Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 28226. Отображено 100.
05-01-2012 дата публикации

Solid Dosage Forms Of Bendamustine

Номер: US20120003309A1
Принадлежит: ASTELLAS DEUTSCHLAND GMBH

In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.

Подробнее
05-01-2012 дата публикации

Method of reducing multi-drug resistance using inositol tripyrophosphate

Номер: US20120003327A1
Принадлежит: Individual

Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.

Подробнее
05-01-2012 дата публикации

Chroman derivatives, medicaments and use in therapy

Номер: US20120004296A1
Принадлежит: Marshall Edwards Inc

Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Подробнее
26-01-2012 дата публикации

Animal treatment formulation and methods of use

Номер: US20120022038A1
Принадлежит: Mastitis Res Centre Ltd

The present invention relates to a formulation for administration to the teat canal of the mammary gland of an animal, the formulation including: a physical barrier material, characterised in that the formulation includes sufficient antibiotic in relation to physical barrier material such that the formulation is configured to disintegrate over a period of time after administration to the teat canal.

Подробнее
02-02-2012 дата публикации

Methods for treating adult respiratory distress syndrome

Номер: US20120027742A1
Принадлежит: Columbia University of New York

We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS.

Подробнее
08-03-2012 дата публикации

Use of over expression of cystathionine gamma lyase as a prognostic, diagnostic and therapeutic target for cancer

Номер: US20120058204A1

The present invention relates to a method of identifying an expression level of cystathionine gamma lyase (CTH) in a sample from a subject. The present invention further discloses a method of diagnosing a subject with cancer having risk of resistance to a platinum-based drug. The present invention also discloses a method for improving efficacy of a platinum-based drug in a subject suffering a cancer.

Подробнее
12-04-2012 дата публикации

Interlaced method for treating cancer or a precancerous condition

Номер: US20120088807A1
Принадлежит: TAU THERAPEUTICS LLC

The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G 2 and M phases of the cell cycle to increase the proportion of the eukaryotic cells in the G 1 phase, stopping administration of the T type calcium channel inhibitor for a period of time, and administering a dosage selected from the group consisting of a dosage of at least one chemotherapeutic agent, a dosage of radiation, and combinations thereof, to kill the proportion of eukaryotic cells progressing past the G 1 phase of the cell cycle after the stopping of the administration of the T type calcium channel inhibitor.

Подробнее
19-04-2012 дата публикации

Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof

Номер: US20120093918A1
Принадлежит: SOCPRA Sciences Sante et Humaines sec

A combination of an anti-cancer agent and a metal radiosensitizer potentiates the radiotherapy of cancer. Said anti-cancer agent is preferably cisplatin while the metal radiosensitizer is preferably gold nanoparticles. Both the anti-cancer agent and the metal radiosensitizer bind to DNA and potentiate the radiotherapy of cancer by synergistically increases the amount of double strand breaks induced by the radiation. The anti-cancer agent and the metal radiosensitizer may be encapsulated in liposomes.

Подробнее
24-05-2012 дата публикации

Pentamidine combinations for treating cancer

Номер: US20120128667A1
Принадлежит: Oncozyme Pharma Inc

The present invention relates to the treatment of cancer, e.g., ovarian cancer, breast cancer, pancreatic cancer or colon cancer, with pentamidine and (a) oxaliplatin, (b) gemcitabine, (c) taxol, (d) 5-fluorouracil or (e) CPT 11.

Подробнее
24-05-2012 дата публикации

Trace Elements

Номер: US20120128792A1
Автор: William Alfred Smith
Принадлежит: Individual

The inventions discloses a trace element solution, which comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.

Подробнее
31-05-2012 дата публикации

Topical Compositions Comprising An Alkoxylated Diphenylacrylate Compound And An Aryl Carboxylic Ester

Номер: US20120134943A1
Принадлежит: ELC Management LLC

A topical composition containing an alkoxylated diphenylacrylate compound and an aryl carboxylic ester is provided. Preferably, the topical composition is a sunscreen composition containing α-ethylhexyl α-cyano-β-(4-methoxyphenyl)-β-phenylacrylate and 2-phenylethyl benzoate, and optionally further containing 4,4′-t-butyl methoxydibenzoylmethane, which is characterized by improved photo-protection of the skin and is effective in preventing/reducing photo-damage of the skin upon exposure to sunlight or other sources of light in the ultraviolet (UV), visible, and infrared (IR) ranges.

Подробнее
14-06-2012 дата публикации

Binary and tertiary galvanic particulates and methods of manufacturing and use thereof

Номер: US20120148633A1

The present invention relates to galvanic particulates, their methods of manufacture and uses in treatments are described. The galvanic particulates may be binary or tertiary galvanic particulates, for example, containing multiple layers or phases of conductive materials.

Подробнее
21-06-2012 дата публикации

Combination therapy for cancer comprising a platinum-based antineoplastic agent and a biocompatible electron donor

Номер: US20120156311A1
Автор: Qing-bin LU
Принадлежит: Individual

The combination of a biocompatible electron donor and a platinum-based antineoplastic agent exhibits improved efficacy in treating cancer This improved activity appears to be the result of electron transfer from the aforementioned donor compound to the platinum-based antineoplastic agent As the electron donor alone has no chemotherapeutic utility in treating cancer, the resulting combinations appear to be synergistic in nature In select preferred embodiments, the biocompatible electron donor is an amine (such as N,N,N′,N′-tetramethyl-p-phenylene diamine or indocyanine green), a phenolic compound (such as a flavanol or catechin), or a quinone (such as an aromatic quinone), while the antineoplastic is cisplatin.

Подробнее
05-07-2012 дата публикации

Chroman derivatives, medicaments and use in therapy

Номер: US20120172424A1
Принадлежит: Marshall Edwards Inc

Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Подробнее
12-07-2012 дата публикации

Metal Abstraction Peptide (MAP) Tag and Associated Methods

Номер: US20120177580A1
Принадлежит: University of Kansas

Compositions comprising a tripeptide having the sequence XC 1 C 2 ; wherein X is any amino acid such that XC 1 C 2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C 1 and C 2 are the same or different; and wherein C 1 and C 2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC 1 C 2 complexes and methods for forming such complexes.

Подробнее
12-07-2012 дата публикации

Compositions for anorectal use and methods for treating anorectal disorders

Номер: US20120177582A1
Автор: Jose E. Ramirez
Принадлежит: Individual

Compositions containing polymetal complexes useful in treating anorectal disorders.

Подробнее
19-07-2012 дата публикации

Low viscosity liquid polymeric delivery system

Номер: US20120183629A1
Автор: Richard L. Dunn
Принадлежит: DUNN RES AND CONSULTING LLC

Low viscosity biodegradable polymer solutions of a liquid biodegradable polymer and biocompatible solvent and methods of using the compositions to form a biodegradable liquid polymer implant are provided.

Подробнее
26-07-2012 дата публикации

Compositions and methods using microspheres and non-ionic contrast agents

Номер: US20120189552A1
Автор: Philippe Reb
Принадлежит: Biosphere Medical SA

The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

Подробнее
09-08-2012 дата публикации

Method

Номер: US20120201864A1
Принадлежит: Cytochroma Development Inc

There is provided a method of producing a mixed metal compound comprising at least Mg 2+ and at least Fe + having an aluminium content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 A) comprising the steps of: (a) combining a Mg 2+ salt and a Fe 3+ salt with Na 2 CO 3 and NaOH to produce a slurry, wherein the pH of the slurry is maintained at from 9 5 to 1 1, and wherein the Na 2 CO 3 is provided at an excess of 0 to 4.0 moles than is required to complete the reaction (b) subjecting the slurry to mixing under conditions providing a power per unit volume of 0 03 to 1.6 kW/m 3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product either by (i) heating the crude product to a temperature of no greater than 150° C. and sufficient to provide a water evaporation rate of 0.05 to 1 5 kg water per hour per kg of dry product, or (H) exposing the crude product to rapid drying at a water evaporation rate of 500 to 50000 kg water per hour per kg of dry product.

Подробнее
30-08-2012 дата публикации

Tri-amino releasing fulvate

Номер: US20120220752A1
Автор: Steven R. Schutt
Принадлежит: Individual

A free amino acid and/or amino ion-releasing molecule useful for a wide variety of medical and cosmetic applications. The chemical name of the new molecule nino-gl ino-parabenzoate, sometimes referred to herein as TAFA. Its chemical structure is graphically depicted according to structure VIII

Подробнее
01-11-2012 дата публикации

Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same

Номер: US20120276162A1
Принадлежит: Individual

The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

Подробнее
15-11-2012 дата публикации

pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof

Номер: US20120288531A1
Принадлежит: Individual

The pharmaceutical compositions described comprise a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer for oral delivery. Some pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer (e.g. a salt of a medium chain fatty acid) and a lipophilic medium. The pharmaceutical compositions may be enteric-coated. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. The methods of treatment described herein increase the level of iron in the bloodstream of a subject by administering to the subject an effective amount of an oral composition of a ferric iron compound.

Подробнее
15-11-2012 дата публикации

Rare earth nanoparticles

Номер: US20120288535A1

This document provides methods and materials related to rare earth particles such as rare earth nanorods (e.g., inorganic lanthanide hydroxide nanorods). For example, rare earth (e.g., lanthanide) particles such as europium hydroxide nanorods, methods and materials for making rare earth particles (e.g., europium hydroxide nanorods), and methods and materials for using rare earth particles (e.g., europium hydroxide nanorods) as an imaging agent and/or to promote angiogenesis are provided.

Подробнее
15-11-2012 дата публикации

Method for controlling toxicity of metallic particle and low-toxicity composite of metallic nanoparticle and inorganic clay

Номер: US20120288553A1
Принадлежит: National Taiwan University NTU

The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nano silicate platelets.

Подробнее
22-11-2012 дата публикации

Chlorite in the Treatment of Neurodegenerative Disease

Номер: US20120295296A1
Автор: Michael S. Mcgrath
Принадлежит: UNIVERSITY OF CALIFORNIA

The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.

Подробнее
03-01-2013 дата публикации

Inhibitors of brutons tyrosine kinase for the treatment of solid tumors

Номер: US20130005746A1
Принадлежит: Pharmacyclics LLC

Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

Подробнее
31-01-2013 дата публикации

Compositions and methods for the treatment of cancer

Номер: US20130029959A1
Принадлежит: Massachusetts Institute of Technology

The present invention relates to compositions, kits, and methods for treatment of cancers. In some cases, the composition comprises a platinum compound comprising a phenanthridine ligand.

Подробнее
07-02-2013 дата публикации

Gallium compositions for the treatment of liver cancer and methods of use

Номер: US20130034617A1
Принадлежит: Individual

Provided are compositions and methods to treat liver cancer and related disorders in human or veterinary individuals. Primary liver cancers, including those metastatic to other parts of the body, as well as many cancers metastatic to the liver, can be treated. The treatments comprise the administration of pharmaceutically acceptable gallium compositions, including gallium maltolate. Routes of administration include, without limitation, oral, intravenous, intratumoral, and in association with chemoembolization.

Подробнее
07-03-2013 дата публикации

Treatment of solid tumors with rapamycin derivatives

Номер: US20130059877A1
Принадлежит: Individual

Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.

Подробнее
21-03-2013 дата публикации

Pharmaceutical Formulations for Iontophoretic Delivery of Gallium

Номер: US20130072899A1
Принадлежит: Nitric BloTherapeutics, Inc.

Pharmaceutical formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of gallium to at least one body surface are described and methods for administering gallium to a body surface via iontophoresis. In one embodiment, the body surface is human skin. 1. A formulation suitable for iontophoresis comprising gallium nitrate in a buffer wherein the buffer has an ionic strength from about 0.01 to about 1 M and wherein the formulation comprises a gallium species selected from the group consisting of gallium citrate species and gallium hydroxide species.2. The formulation of claim 1 , wherein the buffer is a citrate buffer claim 1 ,3. The formulation of claim 2 , wherein the buffer has an ionic strength from about 0.05 M to about 0.10 M.4. The formulation of claim 1 , wherein the formulation has a pH from about 2 to about 12.5. The formulation of claim 2 , wherein the formulation has a pH from about 2 to about 12.6. The formulation of claim 5 , wherein the formulation has a pH from about 3 to about 4.7. The formulation of claim 5 , wherein the formulation has a pH from about 6 to about 12.8. The formulation of claim 5 , wherein the formulation has a pH from about 7 to about 8.9. The formulation of claim 2 , wherein the formulation comprises from about 0.1 to about 20% w/v gallium nitrate.10. The formulation of claim 9 , wherein the formulation comprises from about 15% to about 20% w/v gallium nitrate.11. The formulation of claim 10 , wherein the formulation comprises from about 16 to about 17% w/v gallium nitrate.12. The formulation of claim 11 , wherein the formulation comprises about 16.7% w/v gallium nitrate.13. The formulation of claim 12 , wherein the formulation has a pH from about 7 to about 8 and wherein the buffer has ionic strength of about 1 M.14. A formulation suitable for cathodal iontophoresis comprising gallium nitrate in a citrate buffer wherein the buffer has an ionic strength of about 0.05 M and wherein the formulation ...

Подробнее
28-03-2013 дата публикации

Method of Treating Cancer

Номер: US20130078288A1
Автор: Yu Chun Ho
Принадлежит:

A method and composition for administering a therapeutic composition to a lesion comprising about 20% to about 50% ethanol and other novel therapeutic agents. 1. A therapeutic composition for treatment of hepatic solid tumors comprising a fatty acid mixture and ethanol wherein the ratio of said fatty acid mixture to ethanol is about 1 to 1 to about 5 to 1 and maybe retained in said tumors from about 15 month to about 51 month.2. The therapeutic composition for treating hepatic solid tumors of wherein the said fatty acid mixture is a combination of fatty acids comprising of linolenic acid claim 1 , linoleic acid claim 1 , and oleic acid.3. The therapeutic composition for treating hepatic solid tumors of further comprising a therapeutic agent which may comprise of cisplatin claim 1 , paclitaxol claim 1 , doxorubicin claim 1 , and/or ethanol.4. The therapeutic composition for treating hepatic solid tumors of further comprising a hyperthermia therapy agent.5. The therapeutic composition for treating hepatic solid tumors of wherein said hyperthermia therapy agent comprise of iron oxide nanoparticles with a diameter of approximately 20 to 30 nanometers.6. The therapeutic composition for treating hepatic solid tumors of wherein said hyperthermia therapy agent comprise of tantalum nanoparticles or microparticles.7. The therapeutic composition for treating hepatic solid tumors of wherein the said composition may be administered to a solid tumor by intra-arterial injection that carries blood to the tumor and is retained in a solid tumor claim 1 , occludes arterial vasculature of said solid tumor and occludes portal venous vessels that supply liver tumors.8. The composition for treating hepatic solid tumors of where in the said therapeutic composition serves as a embolic agent claim 1 , sclerosing agent and a chemical ablative agent.9. A method of treating hepatic solid tumors by administering a therapeutic composition to the solid tumors comprising:combining a therapeutic ...

Подробнее
04-04-2013 дата публикации

Compositions, kits and methods for nutrition supplementation

Номер: US20130084344A1
Принадлежит: Chemo France SA

The present invention relates to compositions, kits and methods for the administration of various vitamin, mineral and nutrient compositions, and in a specific embodiment, the compositions, kits and methods may utilize or include twelve carbon chain fatty acids and/or twelve carbon chain acylglycerols, vitamin D, iodine, vitamin B1, vitamin B6, vitamin B12, vitamin B2, vitamin B9, vitamin B3, vitamin E, vitamin A, vitamin C, iron, zinc, copper, magnesium, omega 3 fatty acids and one or more pharmaceutically acceptable carriers.

Подробнее
04-04-2013 дата публикации

INDIBULIN THERAPY

Номер: US20130084345A1
Принадлежит: ZIOPHARM ONCOLOGY, INC.

The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin. 1. A method for treating cancer , comprising administering indibulin or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents , wherein the combination shows efficacy that is greater than the efficacy of either agent being administered alone.2. A method of claim 1 , wherein the indibulin or a pharmaceutically acceptable salt thereof is administered orally.3. A method of claim 1 , wherein the indibulin or a pharmaceutically acceptable salt thereof is administered intravenously.4. A method of claim 1 , wherein the indibulin and the one or more other therapeutic agents are synergistic.5. A method of claim 1 , wherein the indibulin and the one or more other therapeutic agents are additive.6. A method of claim 1 , wherein the other therapeutic agent is selected from erlotinib claim 1 , carboplatin claim 1 , 5-fluorouracil claim 1 , capecitabine claim 1 , paclitaxel claim 1 , tamoxifen claim 1 , vinorelbine claim 1 , cisplatin claim 1 , gemcitabine claim 1 , estramustine claim 1 , doxorubicin claim 1 , vinblastine claim 1 , etoposide claim 1 , and prednisolone.7. A method of claim 1 , wherein the cancer is selected from lung claim 1 , breast claim 1 , ovarian claim 1 , and prostate cancer.8. A method of claim 1 , wherein the compound and the one or more other therapeutic agents are administered simultaneously.9. A method of claim 1 , wherein the one or more other therapeutic agents are administered within about 5 minutes to within about 48 hours prior to or after administration of the compound.10. A method of claim 9 , wherein the ...

Подробнее
11-04-2013 дата публикации

ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE

Номер: US20130089555A1
Принадлежит: Genentech Inc

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Подробнее
11-04-2013 дата публикации

MicroRNA-130a,b as a Tumor Suppressor and Sensitizing Agent for Chemotherapy

Номер: US20130089597A1
Принадлежит:

The present invention provides a method of improving a therapeutic response to a cancer treatment, in a subject, the method comprising administering an effective amount of an agent that enhances the expression of microRNA-130 or an agent that mimics the effects of microRNA-130. Further provided is a method of treating a cancer in a subject in need of such treatment comprising the step of administering an effective amount of a microRNA-130 or an agent that enhances the expression of microRNA-130. 1. A method of providing a prognosis for ovarian cancer in a subject , comprising the steps of:obtaining a biological sample from said subject; andtesting said biological sample to determine whether or not microRNA-130 is under-expressed in said sample, relative to the expression of microRNA-130 in a control sample, whereby the under-expression of microRNA-130 in said biological sample indicates that a tumor in said subject is resistant to a chemotherapy.2. A method of improving a therapeutic response to a cancer treatment , in a subject , the method comprising administering an effective amount of an agent that enhances the expression of microRNA-130 or an agent that mimics the effects of microRNA-130.3. The method of claim 2 , whereby said agent is microRNA-130a or microRNA-130b.4. The method of claim 2 , whereby said agent is a double-stranded miRNA mimic.5. The method of claim 2 , whereby said agent is an oligonucleotide based pre-microRNA-130 drug.6. The method of claim 2 , whereby said cancer is selected from the group consisting of lung cancer claim 2 , pancreatic cancer claim 2 , skin cancer claim 2 , hematological neoplasms claim 2 , breast cancer claim 2 , brain cancer claim 2 , colon cancer claim 2 , follicular lymphoma claim 2 , bladder cancer claim 2 , cervical cancer claim 2 , endometrial cancer claim 2 , esophageal cancer claim 2 , gastric cancer claim 2 , head and neck cancer claim 2 , multiple myeloma claim 2 , liver cancer claim 2 , lymphomas claim 2 , oral ...

Подробнее
11-04-2013 дата публикации

Methods and Compositions for Treating Thyroid-Related Medical Conditions with Reduced Folates

Номер: US20130089623A1
Автор: III Linzy O., Scott
Принадлежит:

The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein. 120-. (canceled)21. A method of treating decreased folate in cerebrospinal fluid , comprising:a. selecting an individual with hyperthyroidism; andb. administering a composition comprising a folate to the individual.22. The method of claim 21 , wherein the folate is a reduced folate.23. The method of claim 21 , wherein the folate is L-methylfolate.24. The method of claim 21 , further comprising the administration of vitamin B12 to the individual.25. The method of claim 21 , wherein the individual has a masked megaloblastic anemia.26. The method of claim 21 , wherein the individual has a masked macrocytic anemia.27. The method of claim 21 , wherein the individual has a macrocytic anemia.28. The method of claim 21 , wherein the individual has a normocytic anemia.29. The method of claim 21 , wherein the individual has a microcytic anemia.30. The method of claim 21 , wherein the individual has one or more of the following:megaloblastic anemia, pancytopenia, aplastic anemia, neutropenia, agranulocytosis, thrombocytopenia, ...

Подробнее
11-04-2013 дата публикации

Compounds Useful as Inhibitors of ATR Kinase

Номер: US20130089624A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 2. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.3. A method for treating cancer in a patient comprising administering a compound of or a pharmaceutically acceptable derivative thereof.4. The method of claim 3 , further comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.56-. (canceled)76. The method of claim claim 3 , wherein said DNA-damaging agent is selected from ionizing radiation claim 3 , a platinating agent claim 3 , a Topo I inhibitor claim 3 , a Topo II inhibitor claim 3 , an antimetabolite claim 3 , an alkylating agent claim 3 , or an alkyl sulphonates.816-. (canceled)176. The method of claim claim 3 , wherein the DNA-damaging agent is selected from one or more of the following: Cisplatin claim 3 , Carboplatin claim 3 , gemcitabine claim 3 , Etoposide claim 3 , Temozolomide claim 3 , or ionizing radiation.18. (canceled)19. The method of claim 3 , wherein said cancer is selected from a cancer of the ...

Подробнее
11-04-2013 дата публикации

Compounds Useful as Inhibitors of ATR Kinase

Номер: US20130089625A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 2. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.3. A method for treating cancer in a patient comprising administering a compound of or a pharmaceutically acceptable derivative thereof.4. The method of claim 3 , further comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.5. The method of claim 4 , wherein said DNA-damaging agent is selected chemotherapy or radiation treatment.6. (canceled)7. The method of claim 6 , wherein said DNA-damaging agent is selected from ionizing radiation claim 6 , a platinating agent claim 6 , a Topo I inhibitor claim 6 , a Topo II inhibitor claim 6 , an antimetabolite claim 6 , an alkylating agent claim 6 , or an alkyl sulphonates.8. (canceled)9. The method of claim 7 , wherein said platinating agent is selected from Cisplatin claim 7 , Oxaliplatin claim 7 , Carboplatin claim 7 , Nedaplatin claim 7 , Lobaplatin claim 7 , Triplatin ...

Подробнее
11-04-2013 дата публикации

Treating Cancer with ATR Inhibitors

Номер: US20130089626A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

This invention relates to methods and compositions for treating pancreatic cancer. More specifically, this invention relates to treating pancreatic cancer with certain ATR inhibitors in combination with gemcitabine and/or radiation therapy. This invention also relates to methods and compositions for treating non-small cell lung cancer. More specifically, this invention relates to treating non-small cell lung cancer with an ATR inhibitor in combination with cisplatin or carboplatin, etoposide, and ionizing radiation. 2. The method of claim 1 , wherein the method increases the sensitivity of pancreatic cancer cells to a cancer therapy selected from gemcitabine or radiation therapy.3. The method of claim 1 , wherein the cancer therapy is gemcitabine.4. The method of claim 1 , wherein the cancer therapy is radiation therapy.5. The method of claim 2 , wherein the pancreatic cancer cells are hypoxic pancreatic cancer cells.7. The method of claim 5 , wherein the cancer therapy is radiation therapy.8. The method of claim 5 , wherein the cancer therapy is gemcitabine.9. The method of claim 2 , wherein the cancer therapy comprises chemoradiation.10. The method of wherein the chemotherapy is gemcitabine.13. The method of wherein the pancreatic cancer cells are derived from a pancreatic cell line selected from PSN-1 claim 12 , MiaPaCa-2 or Panc-1.14. The method of claim 12 , wherein the pancreatic cancer cells are in a cancer patient.1516-. (canceled)18. The method of claim 17 , comprising administering to a patient a compound of formula 821 or 822 in combination with a cancer therapy selected from the group consisting of Cisplatin or Carboplatin claim 17 , Etoposide claim 17 , and ionizing radiation.19. The method of claim 18 , wherein the cancer therapy is Cisplatin or Carboplatin and Etoposide.20. The method of claim 18 , wherein the cancer therapy is Cisplatin or Carboplatin and Etoposide and ionizing radiation.21. The method of claim 18 , wherein the cancer therapy is ...

Подробнее
11-04-2013 дата публикации

SODIUM-HYPOCHLORITE-BASED BODY WASH COMPOSITIONS

Номер: US20130089628A1
Принадлежит: TOPMD, INC.

Sodium hypochlorite-based compositions that are non-toxic and have antimicrobial and cleansing properties may include from about 0.025% to about 10% by weight of sodium hypochlorite. For example, the compositions may include less than 1% by weight of sodium hypochlorite (e.g., less than 0.5% by weight of sodium hypochlorite). The compositions may further include sodium laureth sulfate, cocamidopropyl betaine, cocamide MEA, disodium EDTA, and deionized water. Such compositions may be applied externally to a mammalian body through rinse-off or leave-on applications. Compositions also may be incorporated as a component of other products, such as deodorants, towelettes, or powders. 1. A body wash composition comprising:from 0.1 wt % to 10 wt % of an alkali metal or alkaline earth metal hypochlorite;an anionic surfactant that includes an alkyl sulfate;a nonionic surfactant that includes an alkonolamide;an amphoteric surfactant; anda chelating agent.2. The body wash composition of claim 1 , wherein the anionic surfactant ranges from 3 wt % to 40 wt % of the body wash composition claim 1 , the nonionic surfactant ranges from 1 wt % to 7 wt % of the body wash composition claim 1 , the amphoteric surfactant ranges from 0.5 wt % to 7 wt % of the body wash composition claim 1 , and the chelating agent ranges from approximately 0.1 wt % to 3 wt % of the body wash composition.3. The body wash composition of claim 2 , further comprising water.4. The body wash composition of claim 1 , wherein the alkyl sulfate includes at least one of sodium lauryl sulfate claim 1 , triethanol amine lauryl sulfate claim 1 , ammonium lauryl sulfate claim 1 , and sodium laureth sulfate.5. The body wash composition of claim 4 , wherein the alkyl sulfate includes sodium laureth sulfate.6. The body wash composition of claim 1 , wherein the alkonolamide includes at least one of cocamide monoethanolamide claim 1 , cocamide diethanolamide claim 1 , lauramide monoethanolamide claim 1 , and lauramide ...

Подробнее
11-04-2013 дата публикации

Method for treating brain cancer

Номер: US20130090321A1
Принадлежит: Niiki Pharma Inc

Methods and compositions for treating brain cancer are disclose including refractory brain cancer.

Подробнее
18-04-2013 дата публикации

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

Номер: US20130095193A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 2. The compound of claim 1 , wherein{'sub': 1-4', '1-4, 'J is halo, Calkyl, or Calkoxy;'}{'sup': '1', 'sub': 'q', 'Jis —(X)—Y;'}{'sub': 1-6', '1-6', '1-3, 'X is Calkyl wherein 0-2 methylene units of said Calkyl are replaced with NH, O, or S; X is optionally substituted with 1-2 occurrences of Calkyl or halo;'}{'sup': '1', 'sub': '1-3', 'or J and Jjoin together to form a 5-7 heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or Calkyl;'}{'sup': '4', 'Jis CN or L-Z;'}{'sub': '2', 'L is C(O), S(O), or C(O)NR;'}{'sub': t—', '1-6', '1-6, 'Z is (U)Q or Calkyl wherein 0-2 methylene units of said Calkyl are replaced with O or NR;'}{'sub': '1-2', 'U is Calkyl;'}t is 0 or 1;{'sub': '3-6', 'Q is Ccycloalkyl or 4-6 membered saturated or partially saturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; and'}{'sub': '1-4', 'R is H or Calkyl.'}3. The compound of claim 2 , wherein{'sup': '4', 'Jis CN or L-Z;'}{'sup': '5', 'Jis H;'}{'sup': '3', 'sub': '1-6', 'Jis Calkyl;'}{'sub': 1-4', '1-3, 'Y is hydrogen, Calkyl, or a 3-6 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms ...

Подробнее
18-04-2013 дата публикации

Use of inhaled nitrous oxide or xenon for preventing neuropathic pain caused by cancer chemotherapy

Номер: US20130095194A1

The invention relates to a gaseous inhalable medicament containing xenon or N 2 O as active ingredient for use by inhalation for preventing and/or for treating neuropathic pain or pains caused by at least one cancer chemotherapy substance administered to a patient suffering from cancer, in particular a patient suffering from breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, rectal cancer or a gastric cancer or cancer of the upper aerodigestive tracts. The cancer chemotherapy substance contains one or more compounds chosen from platinum salts, taxanes, alkaloids, thalidomide and bortezomib, in particular paclitaxel, docetaxel or oxaliplatin. The effective volume proportion of nitrous oxide or of xenon is between 5 and 70%.

Подробнее
25-04-2013 дата публикации

Compositions and methods for treating nephropathy

Номер: US20130101514A1
Автор: Daniel Joseph Cushing
Принадлежит: Complexa Inc

Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat nephropathy, and methods for preparing activated fatty acids are provided herein.

Подробнее
25-04-2013 дата публикации

METHODS AND COMPOSITIONS FOR CONTRIBUTING TO THE TREATMENT OF CANCERS

Номер: US20130101552A1
Принадлежит:

Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ET) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide). 1. A method of selectively increasing delivery of a chemotherapeutic agent to an ovarian tumor comprising administering to a mammal in need thereof an IRL-1620 and a chemotherapeutic agent.2. The method according to claim 1 , wherein said IRL-1620 selectively increases blood flow to said ovarian tumor thereby increasing said delivery of said chemotherapeutic agent to said ovarian tumor.3. The method according to claim 1 , wherein the pharmacokinetic properties of said chemotherapeutic agent are not affected by said IRL-1620.4. The method according to claim 1 , wherein said IRL-1620 enhances the efficacy of said chemotherapeutic agent.5. The method according to claim 1 , wherein said IRL-1620 and said chemotherapeutic agent are administered simultaneously.6. The method according to claim 1 , wherein said IRL-1620 and said chemotherapeutic agent are administered sequentially.7. The method according to claim 6 , wherein said IRL-1620 is administered at least 15 minutes before said chemotherapeutic agent.8. The method according to claim 6 , wherein said IRL-1620 is administered about 15 minutes to about 120 minutes before said chemotherapeutic agent.9. The method according to claim 6 , wherein said IRL-1620 is administered about 15 minutes to about 60 minutes before said chemotherapeutic agent.10. The method according to claim 6 , wherein said IRL-1620 is administered about 15 minutes to about 30 minutes before said chemotherapeutic agent.11. The method according to claim 1 , wherein said chemotherapeutic agent is adriamycin claim 1 , camptothecin claim 1 , carboplatin claim 1 , cisplatin claim 1 , daunorubicin claim 1 , doxorubicin claim 1 , alpha interferon claim 1 , beta ...

Подробнее
25-04-2013 дата публикации

HAIR GROWTH STIMULANT

Номер: US20130101569A1
Автор: Weston Anthony R.
Принадлежит:

A composition of a mixture of vitamin and herbal supplements. Supplementation of the composition promotes hair growth and thickness by increasing the number of hairs and preventing hair loss. The concentration of the vitamin and herbal supplements in the composition is suitably about 0.01-100%. The composition may comprise a suitable carrier, solvent and/or emulgent. The composition may be, for example, an internally ingested tablet, a capsule, drops or a suspension. This formulation will enhance the hair thickness and provide elements for growing hair in humans and animals. 1. Promoting hair growth and preventing hair loss thereof administering a composition of mixed vitamin and herbal supplements wherein said concentration of a mixed vitamin and herbal supplements is about 0.1%.2. The composition of claim 1 , wherein said composition of vitamin and herbal supplements are a mixture of Biotin claim 1 , Calcium claim 1 , Chromium claim 1 , Copper claim 1 , DHA-docosahexaenoic acid claim 1 , EPA-eicosapentaenoic acid claim 1 , Fish oil claim 1 , Folic acid claim 1 , Ginkgo biloba claim 1 , Ginseng claim 1 , Iodine claim 1 , Iron claim 1 , Magnesium claim 1 , Manganese claim 1 , Molybdenum claim 1 , Niacin claim 1 , Omega-3 claim 1 , Pantothenic acid claim 1 , Riboflavin claim 1 , Saw palmetto claim 1 , Selenium claim 1 , Thiamin claim 1 , Vitamin A claim 1 , Vitamin B12 claim 1 , Vitamin B6 claim 1 , Vitamin C claim 1 , Vitamin D-cholecalciferol claim 1 , Vitamin E claim 1 , Vitamin K claim 1 , and Zinc.3. The composition of claim 2 , wherein said composition comprises a suitable carrier claim 2 , solvent and/or emulgent.4. The composition of claim 2 , wherein said composition is administered in the form of an oral dosage.5. The composition of claim 2 , wherein said oral dosage is in the form of an internally ingested tablet claim 2 , a capsule claim 2 , drops or a suspension.6. The composition of claim 1 , wherein said oral dosage promotes healthy micronutrient ...

Подробнее
25-04-2013 дата публикации

Compositions and Methods for Treating Vaginal Infections and Pathogenic Vaginal Biofilms

Номер: US20130101678A1
Автор: Flynn Dawn, Gordon Suzanne
Принадлежит: TOLTEC PHARMACEUTICALS, LLC

The present invention generally relates to methods and compositions for treating pathogenic vaginal biofilms. More specifically, the invention relates to pharmaceutical compositions comprising a combination of boric acid and diethylaminetetracetic acid (EDTA) and to methods of using such compositions to treat or prevent biofilm formation associated with vaginal infections, such as bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), trichomoniasis or mixed infections. 1. A pharmaceutical composition for treating and/or preventing a vaginal infection and/or pathogenic vaginal biofilms consisting of: a) a therapeutically effective amount of boric acid in the absence of any therapeutic amount of acetic acid , wherein said therapeutically effective amount is sufficient to disrupt the pathogenic vaginal biofilms , and b) optionally , one or more of a surfactant , a gelling agent , a buffer , a preservative , a detergent , an oil , an alcohol , an emulsifier , a solubilizer , a humectant , a bioadhesive , an additional therapeutically active substance , and a pharmaceutically acceptable carrier suitable for vaginal and/or vulvar drug administration.2. The pharmaceutical composition of claim 1 , further comprising a bioactive agent selected from the group consisting of bergamot oil claim 1 , tea tree oil or other essential oils claim 1 , and zinc ion.3. The pharmaceutical composition of wherein the additional therapeutically active substance is a 5-nitroimidazole.4. The pharmaceutical composition of wherein the 5-nitroimidazole is selected from the group consisting of metronidazole and tinidazole.5. An article of manufacture comprising a packaging material and a pharmaceutical composition of within said packaging material.6. A pharmaceutical composition for treating and/or preventing a vaginal infection and/or pathogenic vaginal biofilms comprising a therapeutically effective amount of boric acid and ethylene-diamine-tetra-acetic acid (EDTA) claim 1 , and further ...

Подробнее
25-04-2013 дата публикации

CHOLESTANOL DERIVATIVE FOR COMBINED USE

Номер: US20130101679A1
Принадлежит:

The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): 2. A cancer chemotherapeutic agent according to claim 1 , wherein claim 1 , in formula (1) claim 1 , G is GlcNAc-Gal- or GlcNAc-.3. A cancer chemotherapeutic agent according to or claim 1 , wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent claim 1 , a platinum complex anti-cancer agent claim 1 , a pemetrexed compound claim 1 , and fluorouracil.4. A cancer chemotherapeutic agent according to claim 3 , wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel claim 3 , Docetaxcel claim 3 , Pemetrexed claim 3 , 5-FU claim 3 , Cisplatin claim 3 , Oxaliplatin claim 3 , Cyclophosphamide claim 3 , and Irinotecan.5. A cancer chemotherapeutic agent according to any of to claim 3 , which is a compounding agent.6. A cancer chemotherapeutic agent according to any of to claim 3 , which is in the form of a kit including a drug containing a cholestanol derivative and a drug containing an anti-cancer agent.7. A cancer chemotherapeutic agent according to claim 6 , wherein the drug containing a cholestanol derivative is a liposomal formulation.10. A cancer chemotherapy according to claim 9 , wherein the cholestanol derivative or a cyclodextrin inclusion compound thereof and the anti-cancer agent are administered to a patient in need thereof simultaneously claim 9 , or separately and intermittently. 1. Field of the InventionThe present invention relates to a chemotherapeutic agent for cancer (hereinafter referred to as a “cancer chemotherapeutic agent”) and, more particularly, to a cancer chemotherapeutic agent employing a cholestanol derivative and an anti-cancer agent in combination.2. Background ArtA variety of anti-cancer agents used in chemotherapy for ...

Подробнее
25-04-2013 дата публикации

USE OF CHROMIUM HISTIDINATE FOR TREATMENT OF CARDIOMETABOLIC DISORDERS

Номер: US20130101681A1
Принадлежит:

Provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising chromium and histidine, chromium histidinate complexes, or combinations thereof, to the individual. 1. A method for reducing the risk of developing cardiometabolic syndrome in a subject in need thereof , comprising;identifying a subject at risk of developing cardiometabolic syndrome; andproviding a therapeutically effective amount of a composition consisting essentially of chromium and histidine, a chromium histidinate complex, or a combination thereof to said subject.2. The method of claim 1 , wherein said identification step comprises identifying a subject with at least one condition selected from the group consisting of: insulin resistance claim 1 , cardiovascular disease claim 1 , progressive renal disease claim 1 , end stage renal disease claim 1 , endothelial dysfunction claim 1 , left ventricular hypertrophy claim 1 , cardiac hyperreactivity claim 1 , dyslipidemia claim 1 , hyperglycemia claim 1 , enhanced rennin angiotensin activity claim 1 , aldosterone syndrome claim 1 , impaired pressure natriuresis claim 1 , chronic low grade inflammation claim 1 , diabetes mellitus claim 1 , hypertension claim 1 , atherosclerosis claim 1 , micoralbuminuria claim 1 , obesity claim 1 , depression claim 1 , Syndrome X claim 1 , and polycystic ovary syndrome.3. The method of claim 1 , wherein said identification step comprises identifying an individual that is taking a composition comprising a compound selected from the group consisting of: non-steroidal anti inflammatory compounds claim 1 , oral contraceptives claim 1 , implantable steroid contraceptives claim 1 , hormone replacement therapy claim 1 , beta blockers claim 1 , potassium channel openers ...

Подробнее
25-04-2013 дата публикации

Infrared Emitting Therapeutic Aids and Medical Products

Номер: US20130103120A1
Автор: Salteri Sergio Ettore
Принадлежит:

There is disclosed therapeutic devices or sanitary articles intended for the treatment of diseases and/or disorders of the tonic/postural system, containing a composition which emits and/or reflects light energy in the far infrared spectrum and which includes a ceramic material. Also disclosed is the use of a composition which emits and/or reflects light energy in the far infrared spectrum and which includes a ceramic material in the preparation of therapeutic devices or sanitary articles intended for the treatment of diseases and/or disorders of the tonic/postural system, in particular, orthodontic devices, glasses and plasters. 110-. (canceled)1110121314. A therapeutic device or sanitary article intended for the treatment of diseases and/or disorders of the tonic-postural system , said device or article selected from the group consisting of a self-modelling or personalized bite () , a proprioceptive device () for the treatment of atypical swallowing , a plaster () intended for skin and oral mucosa application , eye glasses () , a shoe insole , and a stocking , said therapeutic device or sanitary article comprising:{'sub': 2', '3', '2', '3', '2', '2', '3', '2', '2', '2', '2', '3', '2', '3, 'a composition capable of emitting and/or reflecting far infrared light energy at a wavelength from 4 to 15 μm and containing from 1 to 60% by weight of a ceramic material selected from the group consisting of AlO, FeO, TiO, CrO, SiO, MgO, ZrO, MnO, COO, and YO.'}121012. The therapeutic device or sanitary article as defined in claim 11 , wherein the device or article is a self-modelling or personalized bite () and said composition forms a layer () enclosed between two layers () of support material conventionally used for preparing said bite.132131. The therapeutic device or sanitary article as defined in claim 12 , wherein between one of the two support layers () and the composition layer () a layer () is interposed of material capable of shielding the infrared light energy ...

Подробнее
02-05-2013 дата публикации

TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS

Номер: US20130108709A1
Принадлежит:

Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression. 1. A method for improving age-related physiological deficits and increasing longevity in a mammal comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.2. The method of wherein said copper antagonist is a linear or branched tetramine capable of binding copper (II).3. The method of wherein said linear or branched tetramine is a copper (II) chelator.4. The method of wherein said linear or branched tetramine is selected from the group consisting of 2 claim 3 ,3 claim 3 ,2 tetramine claim 3 , 2 claim 3 ,2 claim 3 ,2 tetramine claim 3 , and 3 claim 3 ,3 claim 3 ,3 tetramine.5. The method of wherein said copper (II) antagonist is triethylenetetramine.6. The method of wherein said copper (II) antagonist is a triethylenetetramine salt.7. The method of wherein said triethylenetetramine salt is a succinate salt.8. The method of wherein said triethylenetetramine succinate salt is triethylenetetramine disuccinate.9. The method of wherein said composition is a tablet or capsule for oral administration.10. The method of wherein said composition is a long-acting tablet or capsule for oral administration.11. The method of wherein said copper antagonist is selected from the group consisting penicillamine claim 1 , N- ...

Подробнее
02-05-2013 дата публикации

Antimalarial Drug Which Contains 5-Aminolevulinic Acid or Derivative Thereof as Active Ingredient

Номер: US20130108710A1

Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.

Подробнее
02-05-2013 дата публикации

Tri-amino releasing fulvate

Номер: US20130109636A1
Автор: Steven R. Schutt
Принадлежит: Individual

A free amino acid and/or amino ion-releasing molecule useful for a wide variety of medical and cosmetic applications. The chemical name of the new molecule rginino-glycino-parabenzoate Fulvate, sometimes referred to herein as Li-TAFA. Its chemical structure is graphically depicted according to structure VIII

Подробнее
09-05-2013 дата публикации

Peptide for Use in the Treatment of Breast Cancer and/or Bone Metastases

Номер: US20130115210A1
Принадлежит: Merck Patent GmBH

The invention relates to the use of the Peptide of the formula Cyclo-(Arg-Gly-Asp-DPhe-NMe-Val) and/or the pharmaceutically acceptable dervatives, solvates and/or salts thereof, for the manufacture of a medicament for the treatment of breast cancer and/or bone metastases in humans, wherein the medicament is optionally to be used in combination with one or more cancer cotherapeutic agents, preferably selected from a) hormone modulating agents, b) osteoclast activity modulating agents, c) cancer chemotherapeutic agents, and/or d) radiotherapy, alone, concurrently or not in the dosage regime of the present invention. 1. A peptide of the formula Cyclo-(Arg-Gly-Asp-DPhe-NMe-Val) and/or the pharmaceutically acceptable derivatives , solvates and/or salts thereof for use in the treatment of breast cancer and/or bone metastases in humans.2. The peptide according to claim 1 , wherein the treatment comprises the administration of the Cyclo-(Arg-Gly-Asp-DPhe-NMe-Val) claim 1 , the pharmaceutically acceptable derivatives claim 1 , solvates and/or salts thereof to said humans in an amount of 500 mg to 12500 mg per week (and per human).3. The peptide according to claim 1 , wherein the treatment comprises the administration of the Cyclo-(Arg-Gly-Asp-DPhe-NMe-Val) claim 1 , the pharmaceutically acceptable derivatives claim 1 , solvates and/or salts thereof to said patient at least once a week for at least 3 consecutive weeks.4. The peptide according to claim 1 , wherein the treatment of the breast cancer and/or bone metastases additionally comprises the administration of one or more cancer cotherapeutic agents to said humans.5. The peptide according to claim 4 , wherein the one or more cancer cotherapeutic agents are selected from the group consisting of:a) hormone modulating agents,b) osteoclast activity modulating agents,c) cancer chemotherapeutic agents, andd) radiotherapy.6. The peptide according to claim 5 , whereini) the hormone modulating agents according to a) are selected ...

Подробнее
09-05-2013 дата публикации

SUBSTRATE HAVING AN ELECTRON DONATING SURFACE WITH METAL PARTICLES COMPRISING PALLADIUM ON SAID SURFACE

Номер: US20130115262A1
Принадлежит: BACTIGUARD AB

A substrate with an electron donating surface, characterized in having metal particles on said surface, said metal particles having palladium and at least one metal selected from gold, ruthenium, rhodium, osmium, iridium, or platinum, wherein the amount of said metal particles is from about 0.001 to about 8 μg/cm. Examples of coated objects include contact lenses, pacemakers, pacemaker electrodes, stents, dental implants, rupture nets, rupture mesh, blood centrifuge equipment, surgical instruments, gloves, blood bags, artificial heart valves, central venous catheters, peripheral venous catheters, vascular ports, haemodialysis equipment, peritoneal dialysis equipment, plasmapheresis devices, inhalation drug delivery devices, vascular grafts, arterial grafts, cardiac assist devices, wound dressings, intermittent catheters, ECG electrodes, peripheral stents, bone replacing implants, orthopaedic implants, orthopaedic devices, tissue replacing implants, intraocular lenses, sutures, needles, drug delivery devices, endotracheal tubes, shunts, drains, suction devices, hearing aid devices, urethral medical devices, and artificial blood vessels. 1. A device comprising an electron donating surface , wherein said electron donating surface comprises a metal selected from the group consisting of silver and zinc , wherein metal particles are deposited on said surface , said metal particles comprise palladium and at least one metal selected from the group consisting of gold , ruthenium , rhodium , osmium , iridium , and platinum and wherein the amount of said metal particles is from about 0.001 to about 8 μg/cm2.2. The device according to claim 1 , wherein said silver in said electron donating surface is present in an amount of about 0.05 to about 12 μg/cm2.3. The device according to claim 1 , wherein said substrate is a polymeric substrate.4. The device according to claim 3 , wherein said polymeric substrate is selected from the group consisting of latex claim 3 , vinyl claim 3 , ...

Подробнее
09-05-2013 дата публикации

Combinational Liposome Compositions for Cancer Therapy

Номер: US20130115273A1
Принадлежит: Mallinckrodt LLC

The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome. 1. A method for delivering a therapeutic agent to a subject , the method comprising:a) administering to the subject a liposome comprising a therapeutic agent; andadministering to the subject a lipid nanoparticle comprising a non-ionic triggering agent;whereby release of the therapeutic agent from the liposome following administration of the lipid nanoparticle is increased, relative to the release of the therapeutic agent from the liposome without administration of the lipid nanoparticle.2. The method of claim 1 , wherein the liposome comprises one or more lipids selected from the group consisting of a phospholipid claim 1 , a steroid claim 1 , and a cationic lipid.3. The method of claim 2 , wherein the phospholipid is selected from a phophatidylcholine claim 2 , a phosphatidylglycerol claim 2 , a phosphatidylethanolamine claim 2 , a phosphatidylserine claim 2 , a phosphatidylinositol claim 2 , and a phosphatidic acid.4. The method of claim 3 , wherein the phosphatidylcholine is DSPC.5. The method of claim 3 , wherein the phosphatidylglycerol is DSPG.6. The method of claim 3 , wherein the phosphatidylethanolamine is DSPE-PEG(2000).7. The method of claim 2 , wherein the steroid is cholesterol.8. The method of claim 1 , wherein the lipid nanoparticle is selected from the group consisting of a second liposome claim 1 , a micelle claim 1 , and mixtures thereof.9. The method of claim 8 , wherein the lipid nanoparticle is a second liposome.10. The method of claim 9 , wherein the second liposome comprises one or more lipids selected from the group consisting of a phospholipid claim 9 , a steroid claim 9 , and a cationic lipid.11. The method of ...

Подробнее
09-05-2013 дата публикации

METHODS FOR IDENTIFYING AND USING INHIBITORS OF CASEIN KINASE 1 EPSILON ISOFORM FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS

Номер: US20130115309A1
Принадлежит: Fred Hutchinson Cancer Research Center

In one aspect, the invention provides a method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor. In another aspect, the invention provides a method of treating a subject suffering from a tumor comprising myc-driven tumor cells, comprising administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells. 1. A method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor.2. The method of claim 1 , wherein the myc-driven tumor cell is of neural origin.3. The method of claim 2 , wherein the myc-driven tumor cell of neural origin is derived from a primary neuroblastoma tumor claim 2 , a metastatic neuroblastoma tumor or a brain tumor.4. The method of claim 1 , wherein the myc-driven tumor cell is an ovarian cancer cell.5. The method of claim 1 , wherein the myc-driven tumor cell is selected from the group consisting of rhabdomyosarcoma claim 1 , liver cancer claim 1 , melanoma claim 1 , breast cancer claim 1 , colon cancer claim 1 , prostate cancer claim 1 , Burkitt's lymphoma and lung cancer.6. The method of claim 1 , wherein the tumor cell is contacted in vitro.7. The method of claim 1 , wherein the tumor cell is contacted in vivo in a mammalian subject.8. The method of claim 1 , wherein the CSNK1ε inhibitor is a small molecule inhibitor.9. The method of claim 8 , wherein the CSNK1ε inhibitor is selected from the group consisting of IC261 claim 8 , PF-4800567 claim 8 , and PF-670462.10. A method of treating a subject suffering from a tumor comprising myc-driven tumor cells claim 8 , comprising administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells.11. The method of claim 10 , wherein the ...

Подробнее
09-05-2013 дата публикации

Compounds Useful as Inhibitors of ATR Kinase

Номер: US20130115310A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 4. The compound of claim 1 , wherein Ring B is phenyl claim 1 , thienyl claim 1 , or morpholinyl.50. The compound of claim claim 1 , wherein Ring B is phenyl or thienyl.6. The compound of claim 5 , wherein m is 0 and n is 1.70. The compound of claim claim 5 , wherein{'sub': 1-6', '1-6, 'X is Calkyl wherein 0-2 methylene units of said Calkyl are replaced with NH or O;'}{'sub': 1-4', '1-3, 'Y is hydrogen, Calkyl, or a 3-7 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or Calkyl;'}q is 0 or 1.80. The compound of claim claim 5 , wherein Jis —Calkyl claim 5 , —OH claim 5 , —OCH claim 5 , —CHNHCH claim 5 , —CHOH claim 5 , —OCHCHOH claim 5 , —CHNH-(morpholinyl) claim 5 , or morpholinyl.9. The compound of claim 5 , wherein m is 1 and n is 0.100. The compound of claim claim 5 , wherein J is halo.12. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.13. A method for treating cancer in a patient comprising administering a compound of or a pharmaceutically acceptable derivative thereof.140. The method of claim claim 1 , further comprising administering to said ...

Подробнее
09-05-2013 дата публикации

Compounds Useful as Inhibitors of ATR Kinase

Номер: US20130115311A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 2. The compound of claim 1 , wherein Q is phenyl.3. The compound of claim 1 , wherein X is carbon.4. The compound of claim 1 , wherein p is 0; q is 1; and Jis a Caliphatic group wherein one methylene unit is replaced with S(O).5. The compound of claim 4 , wherein Jis —SOCH(CH).6. The compound of claim 5 , wherein Ring B is phenyl.7. The compound of wherein n and m are both 0.9. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.10. A method for treating cancer in a patient comprising administering a compound of or a pharmaceutically acceptable derivative thereof.11. The method of claim 10 , further comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.1227.-. (canceled)28. The method of claim 10 , wherein said cancer is selected from non-small cell lung cancer claim 10 , small cell lung cancer claim 10 , pancreatic cancer claim 10 , biliary tract cancer claim 10 , head and neck cancer claim 10 , bladder cancer claim 10 ...

Подробнее
09-05-2013 дата публикации

Compounds Useful as Inhibitors of ATR Kinase

Номер: US20130115312A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 43. The compound of any one of - claims 1 , wherein Q is phenyl.5. The compound of claim 4 , wherein p is 0; q is 1; and Jis a Caliphatic group wherein one methylene unit is replaced with S(O).6. The compound of claim 5 , wherein Jis SOCH(CH).7. The compound of wherein Ring B is phenyl.8. The compound of claim 1 , wherein n and m are both 0.10. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.11. A method for treating cancer in a patient comprising administering a compound of or a pharmaceutically acceptable derivative thereof.12. The method of claim 11 , further comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.1328-. (canceled)29. The method of claim 11 , wherein said cancer is selected from non-small cell lung cancer claim 11 , small cell lung cancer claim 11 , pancreatic cancer claim 11 , biliary tract cancer claim 11 , head and neck cancer claim 11 , bladder cancer claim 11 , colorectal cancer claim 11 , ...

Подробнее
09-05-2013 дата публикации

Compounds Useful as Inhibitors of ATR Kinase

Номер: US20130115313A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

Подробнее
09-05-2013 дата публикации

Compounds Useful as Inhibitors of ATR Kinase

Номер: US20130115314A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 2. The compound of claim 1 , wherein Ring B is phenyl claim 1 , thienyl claim 1 , or morpholinyl.3. The compound of claim 2 , wherein Ring B is phenyl.4. The compound of claim 1 , wherein Jis H claim 1 , CH claim 1 , OH claim 1 , OCH claim 1 , CHOH claim 1 , CHNHCH claim 1 , CHNH-cyclopropyl claim 1 , CH(CHF)NH claim 1 , CH(CH)NH claim 1 , CHNH-(tetrahydrofuranyl) claim 1 , CHNH-(oxetanyl) claim 1 , or piperazinyl.5. The compound of claim 1 , wherein Q is phenyl.6. The compound of claim 5 , wherein p is 0; q is 1; and Jis a Caliphatic group wherein one methylene unit is replaced with S(O).7. The compound claim 6 , wherein Jis —SOCH(CH).9. The compound of claim 8 , wherein Jis H claim 8 , Calkyl; and Jis Calkyl.10. The compound of claim 8 , Jand Jjoin together to form a 3-6 membered fully saturated monocyclic ring having 0-2 heteroatoms selected from the group consisting of oxygen claim 8 , nitrogen claim 8 , and sulfur.11. The compound of claim 8 , wherein Jis hydrogen claim 8 , methyl or ethyl; Jis methyl or ethyl; or Jand Jjoin together to form cyclopropyl claim 8 , cyclobutyl claim 8 , cyclopentyl claim 8 , piperidinyl claim 8 , or tetrahydropyranyl.12. The compound of claim 1 , whereinRing B is phenyl or thienyl;{'sup': 2', '3, 'Jis methyl and Jis methyl;'}{'sup': '4', ...

Подробнее
16-05-2013 дата публикации

Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents

Номер: US20130121929A1
Принадлежит: AMAG PHARMACEUTICALS, INC.

Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods. 1. A autoclaved unit dose of an iron oxide complex comprising:particles of a superparamagnetic iron oxide coated with a carboxymethylated reduced dextran having between about 1100 micromoles and about 1500 micromoles carboxyl per gram of carboxymethylated reduced dextran, wherein the reduced dextran has an average molecular weight of about 10 kDa, and wherein the particles have a diameter between about 10 nm and about 50 nm, and 'wherein the autoclaved unit dose has about 500 mg to about 600 mg of iron.', 'a biocompatible liquid;'}2. The autoclaved unit dose of claim 1 , wherein the unit dose has less than about 0.1% free iron concentration as determined by atomic absorption spectroscopy on a sample of the unit dose filtered through a 30K molecular weight cutoff micropartition membrane filter.3. The autoclaved unit dose of claim 1 , wherein the particles have a magnetic susceptibility of greater than 20 claim 1 ,000×10cgs.4. A pharmacological composition comprising:an autoclaved colloid comprising particles of a superparamagnetic iron oxide coated with a carboxymethylated reduced dextran, the reduced dextran having an average molecular weight of about 10 kDa; and a biocompatible liquid, ...

Подробнее
16-05-2013 дата публикации

NITROGENATED DERIVATIVES OF PANCRATISTATIN

Номер: US20130121986A1
Принадлежит:

The present invention concerns nitrogenated derivatives of narciclasine and pancratistatin of the following general formula (I) as well as their pharmaceutically acceptable salts. The present invention also concerns the use of these compounds in cancer therapy as well as a method for their preparation. 2. The compound according to claim 1 , wherein the mixture of isomers is a mixture of enantiomers.3. The compound of claim 1 , wherein the mixture of enantiomers is a racemate mixture.5. The method according to claim 1 , wherein Rrepresents a hydrogen atom.6. The method according to claim 1 , wherein Rrepresents a group —C(O)R′ with R′ representing an aryl group optionally substituted.7. The method according to claim 1 , wherein Rrepresents a group —C(O)R′ with R′ representing a phenyl group optionally substituted.8. The method according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , Rand Reach represent a hydrogen atom.9. The compound according to claim 1 , wherein Rand Rrepresent claim 1 , independently of each other claim 1 , a hydrogen atom or a methyl group.11. A method of treating cancer comprising the administration to a person in need thereof of an effective amount of a pharmaceutical composition comprising at least one compound according to and at least one pharmaceutically acceptable excipient.12. The method according to claim 11 , wherein the pharmaceutical composition comprises at least one other active principle chosen from among anti-cancer agents including 6-mercaptopurine claim 11 , fludarabine claim 11 , cladribine claim 11 , pentostatin claim 11 , cytarabine claim 11 , 5-fluorouracile claim 11 , gemcitabine claim 11 , methotrexate claim 11 , raltitrexed claim 11 , irinotecan claim 11 , topotecan claim 11 , etoposide claim 11 , daunorubicin claim 11 , doxorubicin claim 11 , epirubicin claim 11 , idarubicin claim 11 , pirarubicin claim 11 , mitoxantrone claim 11 , chlormethine claim 11 , cyclophosphamide claim 11 , ifosfamide claim 11 , ...

Подробнее
16-05-2013 дата публикации

TRIAZOLOPYRIDINE DERIVATIVES

Номер: US20130121994A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds. 5. The compound according to which is selected from the group consisting of:4-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-3-methoxybenzonitrile;4-{2-[(2,4-dimethoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;4-{2-[(2-methoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;2,6-dimethyl-4-[2-(pyrimidin-5-ylamino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenol;4-{2-[(2,5-dimethoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;4-{2-[(5-fluoro-2-methoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;2-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}benzonitrile;2,6-dimethyl-4-[2-(pyridin-3-ylamino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenol;2,6-dimethyl-4-(2-{[4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenol;2,6-dimethyl-4-(2-{[2-(trifluoromethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenol;4-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}benzonitrile;4-{2-[(2-ethoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;3-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-4-methoxybenzonitrile;4-{2-[(3-methoxypyridin-2-yl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;4-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-N-methylbenzamide;N,N-Diethyl-4-[6-( ...

Подробнее
16-05-2013 дата публикации

Nanotubes as Mitochondrial Uncouplers

Номер: US20130122063A1
Автор: Sullivan Patrick

A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Cainto mitochondria is provided, including administering a pharmaceutically effective amount of nanotubes into the subject. A method of reducing weight, treating cancer, reducing the effects of traumatic brain injury, or reducing the effects of ageing, in a subject including administering a pharmaceutically effective amount of nanotubes into the subject is also provided. 1. A method of reducing the effects of traumatic brain injury in an individual comprising:administering a therapeutically effective amount of nanotubes into the individual, wherein the nanotubes are self-rectifying nanotubes, having a length of less than 50 nm and a conductance such that the nanotubes conduct protons only when a proton gradient of about 120-220 mV is present.2. The method of claim 1 , wherein the individual is a mammal.3. The method of claim 1 , wherein the nanotubes have an inner diameter designed for uncoupling mitochondria.4. The method of claim 1 , wherein the nanotubes have an inner diameter designed for self-rectifying the nanotubes.5. The method of claim 4 , wherein the nanotubes are made from metals or polymers.6. The method of claim 5 , wherein the metals include gold and silver.7. The method of claim 5 , wherein the polymers include natural or synthetic polymers.8. The method of claim 5 , wherein the polymers can be selected from the group consisting of poly(vinyl alcohol) claim 5 , poly(esters) claim 5 , polyglycolide claim 5 , polycaprolactone claim 5 , poly(ethylene oxide) claim 5 , poly(butylene terephthalate) claim 5 , poly(hydroxyalkanoates) claim 5 , hydrogels claim 5 , modified poly(saccharides) claim 5 , starch claim 5 , cellulose claim 5 , and chitosan.9. A method of reducing the effects ...

Подробнее
16-05-2013 дата публикации

Prodrug compositions, prodrug nanoparticles, and methods of use thereof

Номер: US20130122100A1
Принадлежит: Washington University in St Louis WUSTL

Nanoparticles comprising a prodrug and prodrugs linked to phospholipids, wherein the linkages facilitate release of the prodrugs from the nanoparticles to sites within a target cell or cell membrane by fusion of the particle and the cell membrane are disclosed. Also disclosed are methods for producing and using the nanoparticles and their constituents.

Подробнее
16-05-2013 дата публикации

METHOD FOR TREATMENT OF ADVANCED SOLID TUMORS

Номер: US20130122111A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to the use of Volasertib or a salt thereof or a hydrate thereof in combination with Cisplatin or Carboplatin or a salt thereof or a hydrate thereof for treating patients suffering from advanced and/or metastatic solid tumours. 1. A method of treating advanced and/or metastatic solid tumours , comprising administering 300 to 500 mg Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof to a patient at one day during a 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 or 31 day treatment cycle.2. A method of treating advanced and/or metastatic solid tumours , comprising administering a dosage schedule (I) comprising or consisting ofa) 300 to 500 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and{'sup': '2', 'b) 50 to 100 mg/mBSA of Cisplatin at one day within the same treatment cycle,'}to a patient suffering from advanced and/or metastatic solid tumours.3. A method of treating advanced and/or metastatic solid tumours , comprising administering a dosage schedule (I) comprising or consisting ofa) 300 to 500 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle andb) Carboplatin at a dose targeting AUC=4 mg·min/mL to AUC=6 mg·min/mL at one day within the same treatment cycle,to a patient suffering from advanced and/or metastatic solid tumours.4. The method according to or , wherein the treatment cycle is 14 , 21 or 28 days.5. The method according to claim 2 , wherein Volasertib and Cisplatin are administered at the same day.6. The method according to claim 3 , wherein Volasertib and Carboplatin are administered at the same day.7. The method according to claim 5 , wherein Volasertib and Cisplatin are ...

Подробнее
16-05-2013 дата публикации

ANTITUMORAL COMBINATION COMPRISING OMBRABULIN, A TAXANE DERIVATIVE AND A PLATINUM DERIVATIVE

Номер: US20130122113A1
Принадлежит: SANOFI

The invention concerns an antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative and its use in the treatment of advanced solid tumors. 1. A combination of antitumoral agents , wherein said antitumoral agents comprise ombrabulin , a taxane derivative and a platinum derivative , said ombrabulin , said taxane derivative and said platinum derivative each being in the form of a free base , of an addition salt with a pharmaceutically acceptable acid , of a hydrate , or of a solvate , wherein said combination is well tolerated , does not exacerbate the toxicity of each of the antitumoral agents , and allows the treatment of advanced solid tumors either by stabilizing or a tumor or by inducing a partial or a complete regression of a tumor.2. The combination according to wherein ombrabulin is in the form of the hydrochloride salt.3. The combination according to wherein the taxane derivative is chosen from paclitaxel and docetaxel.4. The combination according to wherein the platinum derivative is chosen from cisplatin and carboplatin.5. The combination according to wherein ombrabulin is in combination with docetaxel and cisplatin or in combination with paclitaxel and carboplatin.6. The combination according to comprising an effective quantity of ombrabulin claim 1 , an effective quantity of a taxane derivative and an effective quantity of a platinum derivative.7. The combination according to wherein ombrabulin is administered at a dose of between 15 and 35 mg/m.8. The combination according to wherein ombrabulin is administered at a dose chosen from 15.5 claim 7 , 20 claim 7 , 25 claim 7 , 30 and 35 mg/m.9. The combination according to wherein the taxane derivative is docetaxel and is administered at a dose of 60 or 75 mg/m.10. The combination according to wherein the taxane derivative is paclitaxel and is administered at a dose of 175 or 200 mg/m.11. The combination according to wherein the platinum derivative is cisplatin and is ...

Подробнее
16-05-2013 дата публикации

METHODS AND COMPOSITIONS FOR INHIBITING THE NUCLEAR FACTOR KAPPAB PATHWAY

Номер: US20130122114A1
Принадлежит:

The current invention provides therapeutic methods which include inhibition of nuclear factor κb pathway in a cell based on the discovery of an active fraction of a plant extract termed NUP or a composition which includes NUP. NUP is used in treating and managing different diseases such as cancer, inflammation, and virus infections. 2. The composition of claim 1 , wherein said NUP inhibits a nuclear factor κB pathway in a cell.3Nuphar lutea.. The composition of claim 1 , wherein said Nymphaeaceae is4. A method for treating a subject afflicted with Hodgkin lymphoma claim 1 , melanoma claim 1 , or lung melanoma comprising administering to said subject the composition of .5. A method for enhancing the efficacy of a composition comprising podophyllotoxin drug or a platinum drug claim 1 , comprising the step of combining said composition comprising podophyllotoxin drug or said platinum drug with the composition of .6. The method of claim 5 , wherein said podophyllotoxin drug is etoposide.7. The method of claim 5 , wherein said platinum drug is cisplatin.8. A method for reducing or treating inflammation disease in a subject in need thereof claim 1 , comprising administering to said subject the composition of .9. The method of claim 8 , wherein said reducing or treating inflammation disease is affected by reducing pro-inflammatory cytokines and elevating anti-inflammatory cytokine in the blood of said subject.10. The method of claim 8 , wherein said inflammation disease is inflammatory bowel disease (IBD) claim 8 , ulcerative colitis (UC) or Crohn's disease (CD).11. A method for treating a subject afflicted with Respiratory Syncytial Virus claim 1 , comprising the step of administering to said subject the composition of .12. A method for preventing a cytotoxic effect of a Respiratory Syncytial Virus in a subject claim 1 , comprising the step of administering to said subject the composition of .13. A method of reducing the contagiousness of a subject infected by a ...

Подробнее
23-05-2013 дата публикации

IRON OXIDE NANOPARTICLES FOR USE IN TREATING NON-INFECTIOUS INFLAMMATORY DISORDERS

Номер: US20130129810A1
Принадлежит:

In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders. Also provided by the present disclosure is a method of treatment of non-infectious inflammatory disorders making use of such particles, pharmaceutical compositions and kits comprising such particles 152-. (canceled)53. A method for treating non-infectious inflammatory disorders in a subject , the method comprising providing a subject in need an amount of iron oxide nanoparticles , the amount being effective to treat the non-infectious inflammatory disorders.54. The method of claim 53 , wherein the iron oxide nanoparticles being in naked form claim 53 , surface modified claim 53 , or formulated within a carrier.55. The method of claim 53 , wherein the iron comprises one or both of ferric iron (Fe) and ferrous iron (Fe).56. The method of claim 53 , wherein the iron oxide is selected from the group consisting of magnetic iron oxide claim 53 , ferromagnetic iron oxide claim 53 , ferrimagnetic iron oxide and anti-ferromagnetic iron oxide.57. The method of claim 53 , wherein the iron oxide is superparamagnetic iron oxide.58. The method of claim 53 , wherein the iron oxide nanoparticles is modified with an organic material selected from the group consisting of small molecules claim 53 , surfactants claim 53 , polymers and biomolecules.59. The method of claim 53 , wherein the iron oxide nanoparticles is modified with an inorganic material selected from the group consisting of silica claim 53 , metal substance claim 53 , nonmetal elementary substance claim 53 , metal oxides and metal sulfides.60. The method of claim 53 , wherein the iron oxide nanoparticles are in the form selected from the group consisting of an iron oxide core within a shell of organic or inorganic material; a mosaic form; a core of organic or inorganic material within a shell of iron oxide; a shell-core-shell form; bi-functional dumbbell form.61. The ...

Подробнее
23-05-2013 дата публикации

THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT

Номер: US20130129841A1
Принадлежит: NERVIANO MEDICAL SCIENCES S.R.L.

The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of an alkylating or alkylating-like agent, an antimetabolite agent, a topoisomerase I inhibitor, a topoisomerase II inhibitor, an antimitotic agent and radiation wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof. 2. A combination according to claim 1 , wherein the alkylating or alkylating-like agent is selected from the group consisting of Carboplatin claim 1 , Cisplatin claim 1 , Temozolomide claim 1 , Dacarbazine.3. A combination according to claim 1 , wherein the antimetabolite is Gemcitabine.4. A combination according to claim 1 , wherein the topoisomerase I inhibitor is selected from the group consisting of Irinotecan and Topotecan.5. A combination according to claim 1 , wherein the topoisomerase II inhibitor is nemorubicin.6. A combination according to claim 1 , wherein the antimitotic agent is selected from the group consisting of Paclitaxel and Docetaxel.76. A combination according to claim 1 , wherein in formula (I):{'sub': 1', '2', '1', '2, '(i): when R is hydrogen atom, then Rand Rare both fluorine atoms and, when R is fluorine atom, then Rand Rare both chlorine atoms, fluorine atoms or together form an oxo group (=O), or'}{'sub': 1', '2, '(ii): R is hydrogen atom or fluorine atom, and Rand Rare both fluorine atoms, or'}{'sub': 1', '2, '(iii): R, Rand Rare all fluorine atoms.'}87. A combination according to claim 1 , wherein the compound of formula (I) is selected from the group consisting of:2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide;2-[1-(4,4-difluorocyclohexy)piperidin-4-yl]-6-fluoro-3 -oxo-2,3-dihydro-1H-isoindole-4-carboxamide;6-fluoro-3-oxo-2-[1-(4-oxocyclohexy)piperidin-4-yl]-2,3-dihydro-1H-isoindole-4- ...

Подробнее
30-05-2013 дата публикации

NOVEL MUTATED HUMANIZED 12G4 ANTIBODIES AND THE FRAGMENTS THEREOF AGAINST THE HUMAN ANTI-MULLERIAN HORMONE RECEPTOR TYPE II

Номер: US20130136743A1
Принадлежит:

Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor. 1. Humanized 12G4 monoclonal antibody comprising or consisting of: a variable region the amino acid sequence of which is represented by SEQ ID NO: 2 or SEQ ID NO: 4, and', 'a constant region the amino acid sequence of which is represented by SEQ ID NO: 6 or by a sequence having at least 80% homology with SEQ ID NO: 6,, 'a) a light chain comprising or consisting of a variable region the amino acid sequence of which is represented by SEQ ID NO: 8, or SEQ ID NO: 10, and', 'a constant region the amino acid sequence of which is represented by SEQ ID NO: 12 or by a sequence having at least 80% homology with SEQ ID NO: 12,, 'b) a heavy chain comprising or consisting of{'sub': 'D', 'claim-text': a variable region the amino acid sequence of which is represented by SEQ ID NO: 14, and', 'a constant region the amino acid sequence of which is represented by SEQ ID NO: 6,, 'said humanized 12G4 monoclonal antibody is mutated, comprises at least one mutation in the light and/or heavy chain, and has a Kfor the human anti-Müllerian hormone type II receptor (AMHRII) at least equal to that of the chimeric 12G4 monoclonal antibody comprising or consisting of a variable region the amino acid sequence of which is represented by SEQ ID NO: 18, or SEQ ID NO: 10, and', 'a constant region the amino acid sequence of which is represented by SEQ ID NO: 12,, 'b) a heavy chain consisting of{'sup': −9', '−8', '−9', '−11, 'for said receptor, preferably below 10M, in particular below 10M, in particular in the range from 10M to 10M.'}2. Mutated humanized 12G4 monoclonal antibody according to claim 1 , comprising at least one mutation in at least one CDR of the variable region of the light chain claim 1 , and having an affinity for said receptor at least equal to that of said chimeric 12G4 monoclonal antibody.3. Mutated humanized 12G4 monoclonal antibody according to claim 1 , ...

Подробнее
06-06-2013 дата публикации

COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES

Номер: US20130142805A1
Принадлежит: BRISTOL-MYERS SQUIBB COMPANY

Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. 114-. (canceled)15. A method for the treatment of cancer , comprising the administration to a mammal in need thereof a synergistic , therapeutically effective amount of an anti-CTLA-4 antibody with 2′-deoxy-2′ ,2′-difluorocytidine monohydrochloride (β-isomer) , or a pharmaceutically acceptable salt , solvate , or hydrate thereof.16. The method according to claim 15 , wherein the anti-CTLA-4 antibody is selected from the group consisting of: ipilimumab and tremelimumab.17. The method according to claim 15 , wherein said anti-CTLA-4 antibody is ipilimumab.18. The method according to claim 15 , wherein said cancer is a solid tumor.19. The method according to claim 18 , wherein said solid tumor is selected from the group consisting of: lung carcinoma claim 18 , lung metastasis claim 18 , and colon carcinoma.20. The method according to claim 15 , wherein said method is for the treatment of a tumor refractory to said chemotherapeutic agent.21. The method according to claim 15 , wherein said chemotherapeutic agent is administered before the administration of said anti-CTLA4 antibody.22. The method according to claim 15 , wherein said chemotherapeutic agent is administered essentially simultaneously with the administration of said anti-CTLA4 antibody.23. The method according to claim 15 , wherein said cancer treatment further comprises an anti-proliferative cytotoxic agent either alone or in combination with radiation therapy.24. The method according to claim 23 , wherein said anti-proliferative cytotoxic agent is cisplatin.25. The method according to claim 23 , wherein said anti-proliferative cytotoxic agent is paraplatin.26. The method according to claim 15 , wherein said chemotherapeutic agent is administered at a dose of about 200 mg.27. The method according to claim 15 , wherein said chemotherapeutic agent is administered at a dose of about 1 g.28. The ...

Подробнее
06-06-2013 дата публикации

USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES

Номер: US20130142887A1
Принадлежит: THE JOHNS HOPKINS UNIVERSITY

The present invention provides methods for treating cancer comprising inhibiting the activity of p300/CBP histone acetyltransferase (HAT). Also provided are p300/CBP HAT inhibitors for treating a subject having cancer. In addition, the present invention includes biomarkers for p300/CBP HAT inhibition, which are used to i) monitor the effectiveness of cancer therapy, and ii) identify anti-cancer agents for use in combination therapy. 2. The method of claim 1 , wherein the p300/CBP HAT inhibitor is a p300-selective inhibitor.35.-. (canceled)6. The method of claim 1 , wherein the method further comprises administering radiation therapy or at least one additional anti-cancer agent.7. The method of claim 6 , wherein the anti-cancer agent is a DNA damaging chemotherapeutic agent.8. The method of claim 7 , wherein the DNA damaging chemotherapeutic agent is cisplatin or temozolamide.9. The method of claim 1 , wherein the cancer is leukemia claim 1 , brain cancer claim 1 , lung cancer claim 1 , central nervous system (CNS) cancer claim 1 , melanoma claim 1 , renal cancer claim 1 , prostate cancer claim 1 , colon cancer claim 1 , ovarian cancer claim 1 , or breast cancer.1011.-. (canceled)1316.-. (canceled)1716. The method of claim claim 1 , wherein the method further comprises exposing the cell to radiation therapy or contacting the cell with at least one additional anti-cancer agent.18. The method of claim 17 , wherein the anti-cancer agent is a DNA damaging chemotherapeutic agent.19. The method of claim 18 , wherein the DNA damaging chemotherapeutic agent is cisplatin or temozolamide.20. The method of claim 19 , wherein the neoplastic cell is from a leukemia claim 19 , brain cancer claim 19 , lung cancer claim 19 , CNS cancer claim 19 , melanoma claim 19 , renal cancer claim 19 , prostate cancer claim 19 , colon cancer claim 19 , ovarian cancer claim 19 , or breast cancer.21. (canceled)22. The method of claim 17 , wherein the method is carried out in vitro or in vivo.2427 ...

Подробнее
06-06-2013 дата публикации

Ferrimannitol-ovalbumin tablet composition

Номер: US20130143819A1
Принадлежит: Tedec Meiji Farma SA

The invention refers to an oral pharmaceutical tableted dosage form which comprises a mixture of: a) granules comprising ferrimannitol-ovalbumin (FMOA) and at least an intragranular pharmaceutical acceptable excipient including a binder; and b) extragranular pharmaceutical excipients including a filler and a binder; which may be obtained by wet-granulation and compression.

Подробнее
13-06-2013 дата публикации

MEDICAL COMPOSITIONS CONTAINING LIQUORICE EXTRACTS WITH SYNERGISTIC EFFECT

Номер: US20130149393A1
Автор: Chen Dong, Zhou James
Принадлежит:

The invention provides drug compositions with synergistic effects, which includes alcohol-soluble and water-insoluble liquorices extracts and at least one kind of anti-tumor or glucose-and-lipid-lowering drug/eatable substance, and can be used to treat tumor or lower blood glucose and lipid. Besides, the invention also provides pharmaceutical preparation, pharmaceutical application, therapeutic and preparation methods, etc. related to this drug compositon. 1. Drug compositions with synergistic effects contain alcohol-soluble and water-insoluble liquorices extracts , and at least one kind of anti-tumor or glucose-or/and-lipid-lowering drug/eatable substances , and the preferred composition is composed of alcohol-soluble and water-insoluble liquorices extracts , and one kind of anti-tumor or glucose-and-lipid-lowering drug/eatable substance.2radix glycyrrhizaGlycyrrhiza uralensisglycyrrhiza inflataglycyrrhiza inflata.. The drug composition described in claim 1 , wherein liquorices are including or or their mixture claim 1 , the preferred is their mixture and the much more preferred is the mixture with more than 5%3. The drug compositions described in claim 1 , wherein alcohol-soluble and water-insoluble liquorices extracts are prepared through the methods including the following steps:(1) Reserve the solid parts after extraction of liquorices by water;(2) Reserve and dry the liquid part, after extracting the solid part by the extraction steps (1) with a high concentration alcohol (concentrations is higher than 85% (V/V), the preferred is higher than 90% (V/V), more preferred is higher than 93% ((V/V)), such as 95% (V/V)).4. The drug compositions described in claim 3 , wherein the described methods also include the step to further extract Chalcone A.5. The drug compositions described in claim 1 , wherein the content of liquorices flavonoid in alcohol-soluble and water-insoluble liquorices extracts is higher than 15% claim 1 , or the content of Chalcone A is higher than ...

Подробнее
13-06-2013 дата публикации

Aqueous ophthalmic composition

Номер: US20130149394A1
Принадлежит: Wakamoto Pharmaceutical Co Ltd

The invention provides an aqueous ophthalmic composition, containing a beta blocker such as timolol, carteolol or the like, and a sugar alcohol such as mannitol, sorbitol or the like, optionally together with boric acid. The composition of the invention can improve the corneal permeability of a drug, so that the dose of the drug can be lowered, for example by decreasing the frequency of application to the eyes. It is therefore expected that the risk of systemic side effects which may be induced by the application of the beta blocker to the eyes, including cardiotoxicity or respiratory toxicity can be reduced. The decrease in the frequency of application of ophthalmic solution can favorably improve the QOL and prevent the decrease of therapeutic effect which may be caused by missing the application to the eyes.

Подробнее
13-06-2013 дата публикации

Hemostasis Composition with Magnetite

Номер: US20130150652A1
Принадлежит: Biolife LLC

A composition and method of arresting the flow of blood from a bleeding wound. The composition preferably includes an anhydrous salt ferrate compound preferably combined with an effective amount of an insoluble cation exchange material and an effective amount of anhydrous Magnetite mixed uniformly together. Povidone iodine may be added for enhanced antimicrobial properties. In the method, a quantity of the composition is magnetically attached to a surface of a magnet, after which the powderous mixture is applied to the wound by pressing the surface covered with the powderous compound against the wound for a time sufficient to clot the blood to arrest substantial further blood flow from the wound.

Подробнее
20-06-2013 дата публикации

Substituted Triazolopyridines

Номер: US20130156756A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease of uncontrolled cell growth, proliferation and/or survival as well as to the use of intermediate compounds for the preparation of said compounds. 2. The compound according to claim 1 , wherein:{'sup': '1', 'claim-text': 'which is substituted, one or more times, identically or differently, with a substituent selected from:', 'Rrepresents an aryl or heteroaryl group'}{'sup': 6', '6', '6', '6', '6', '6', '6', '6', '6', '6', '7', '6', '6', '7', '7', '6', '7', '6', '7', '6', '6', '7', '6', '6', '6', '6', '7', '6', '6', '6', '7', '6', '7', '6', '6', '6', '7', '6', '7', '7', '6', '6', '7, 'sub': 2', 'n', '2', 'm', '1', '6', '2', 'n', '2', 'p', '1', '6', '1', '6', '1', '6', '1', '6', '2', '2', '2', '2', '2, 'claim-text': and', {'sup': 'xy', 'which is optionally substituted, one or more times, identically or differently, with a substituent Rselected from, {'sub': 1', '6', '1', '6', '1', '6', '1', '6', '1', '6, 'sup': 8', '7', '8', '8', '8', '7, 'halo-, hydroxyl-, cyano-, C-C-alkyl-, halo-C-C-alkyl-, C-C-alkoxy-, halo-C-C-alkoxy-, hydroxy-C-C-alkyl-, —N(H)C(═O)R, —N(R)C(═O)R, —C(═O)N(H)R, —C(═O)NRR;'}], 'R—(CH)(CHOH)(CH)—, R—(C-C-alkoxy)-, R—(CH)(CHOH)(CH)—O—, R—(C-C-alkoxy-C-C-alkyl)-, R—(C-C-alkoxy-C-C-alkyl)-O—, R—O—, —C(═O)R, —C(═O)O—R, —OC(═O)—R, —N(H)C(═O)R, —N(R)C(═O)R, —N(H)C(═O)NRR, —N(R)C(═O)NRR, —NRR, —C(═O)N(H)R, —C(═O)NRR, R—S—, R—S(═O)—, R—S(═O)—, —N(H)S(═O)R, —N(R)S(═O)R, —S(═O)N(H)R, —S(═O)NRR, —N(H)S(═O)R, —N(R)S(═O)R, —S(═O)N(H)R, —S(═O)NRR, —S(═O)(═NR)R, —S(═O)(═NR)R, —N═S(═O)(R)R;'}or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a ...

Подробнее
20-06-2013 дата публикации

Compositions Using Antibodies Directed To GPNMB And Uses Thereof

Номер: US20130156784A1
Принадлежит:

The present invention relates to antibodies, including fully human monoclonal antibodies, with specificity to GPNMB, and uses of such antibodies. The present invention further provides compositions that increase expression of GPNMB on the surface of tumor cells, and methods of using such compositions to increase the anti-cancer activity or other therapeutic efficacy of the antibodies and immunoconjugates provided herein. 1. A pharmaceutical composition comprising an isolated monoclonal antibody that specifically binds to GPNMB and a second agent that increases expression of GPNMB on a tumor cell or decreases shedding of GPNMB by a tumor cell.2. The composition of claim 1 , wherein the second agent is selected from an inhibitor of the ERK pathway claim 1 , a tyrosine kinase inhibitor claim 1 , an inhibitor of p38 MAPK claim 1 , a lysosomotropic weak base and an inhibitor of GPNMB shedding.3. The composition of claim 1 , wherein the antibody is a human monoclonal antibody.4. The composition of claim 1 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2 claim 1 , 20 claim 1 , 38 claim 1 , 56 claim 1 , 74 claim 1 , 92 claim 1 , 110 claim 1 , 128 claim 1 , 146 claim 1 , 164 claim 1 , 182 claim 1 , 200 claim 1 , 218 claim 1 , 236 claim 1 , 253 claim 1 , 256 claim 1 , 260 claim 1 , 265 claim 1 , 270 claim 1 , 274 claim 1 , 277 claim 1 , 281 and 285; and the antibody comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 11 claim 1 , 29 claim 1 , 47 claim 1 , 65 claim 1 , 83 claim 1 , 101 claim 1 , 119 claim 1 , 137 claim 1 , 155 claim 1 , 173 claim 1 , 191 claim 1 , 209 claim 1 , 227 and 245.6. The composition of claim 1 , wherein the antibody is an IgG1 antibody.7. The composition of claim 1 , wherein said antibody is conjugated to a cytotoxic agent.8. The composition of claim 7 , wherein the cytotoxic agent ...

Подробнее
20-06-2013 дата публикации

HYPERHALOGENS AND HIGHLY ELECTRONEGATIVE COMPOSITIONS

Номер: US20130156866A1
Автор: JENA Puru
Принадлежит: Virginia Commonwealth University

Hyperhalogens, a new class of highly electronegative species, are now invented. A hyperhalogen is a superhalogen-containing composition in which the electron affinity (EA) of the hyperhalogen is even larger than that of the superhalogens they are composed of. Novel production methods are provided in which highly electronegative species are produced by surrounding a central metal atom by superhalogen moieties. 1. A hyperhalogen , comprising:a metal core;at least one superhalogen associated with said metal core, wherein the hyperhalogen composition has an EA higher than an EA of the at least one superhalogen included therein.2. The hyperhalogen of claim 1 , wherein the at least one superhalogen includes a plurality of superhalogens which may be the same or different and each of which is associated with said metal.3. The hyperhalogen of wherein the hyperhalogen has an EA higher than an EA of any superhalogen included therein.4. The hyperhalogen of claim 2 , wherein the EA of the hyperhalogen is at least 1 eV higher than the EA of the at least one superhalogen.5. The hyperhalogen of wherein said metal core is Au-based.6. The hyperhalogen of wherein said metal core is Cu-based.7. An electronegative composition comprising BO2 and having an EA of substantially greater than 4.32 eV.8. The electronegative composition of claim 7 , wherein the EA is 5.54 eV.9. A stable ternary nanocluster comprising superhalogen units as blocking blocks claim 7 , wherein the nanocluster has an electron affinity larger than an electron affinity of any superhalogen making up the nanocluster.10. The stable ternary nanocluster of further comprising a central metal core.11. The composition of claim 10 , wherein the central metal core is Au or Cu.12. The composition of claim 1 , formulated in a product selected from the group consisting of a disinfectant claim 1 , an air cleaner and a mood enhancer.13. A method of obtaining an increased EA for a superhalogen building block claim 1 , comprising:{'b': ...

Подробнее
20-06-2013 дата публикации

Preparation Comprising Iron(III) Complex Compounds And Redox-Active Substance(s)

Номер: US20130157974A1
Принадлежит: Vifor International AG

A preparation is disclosed that comprises one or more iron(III) complex compounds which have a redox potential at pH 7 of from −324 mV to −750 mV relative to a normal hydrogen electrode (NHE), and one or more redox-active substances, wherein the carbohydrates are selected from the group consisting of dextrans and hydrogenated dextrans, dextrins, oxidised or hydrogenated dextrins, as well as pullulan, oligomers thereof and/or hydrogenated pullulans, and wherein the redox-active substance(s) is/are selected from the group consisting of ascorbic acid; vitamin E; cysteine; physiologically acceptable phenols/polyphenols selected from the group consisting of quercetin, rutin, flavones, flavonoids, hydroquinones; and glutathione, and in particular is ascorbic acid.

Подробнее
20-06-2013 дата публикации

Rhenium complexes and their pharmaceutical use

Номер: US20130158109A1

The present invention is directed to a rhenium complex of general Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is Se; Y is NH, O or S or is a methylene group; Z is halogen; m=0, 1, or 2 and p=0, 1, or 2, provided that m and p are both different from zero when Y is NH, O or S; n=3; R′ is a phenyl group or a group of general Formula —(CH 2 ) q —COOH wherein q=1 or 2, a pharmaceutical composition comprising a therapeutically effective amount of at least one of such rhenium complex where X is additionally S or Te, a method for preparing said rhenium complex and a method for treating a proliferative growth related-disorder using a therapeutically effective amount of at least one of said rhenium complex where X is additionally S or Te. Also claimed is the use of compounds of formula (II) in the preparation of compounds of formula (I).

Подробнее
27-06-2013 дата публикации

ORAL COMPOSITIONS COMPRISING A ZINC COMPOUND AND AN ANTI-MICROBIAL AGENT

Номер: US20130164358A1
Принадлежит:

Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one Eh-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier. 1. An oral composition comprising:{'sub': 'h', 'a first component comprising at least one E-raising compound and a pharmaceutically acceptable carrier, and'}a second component comprising at least one zinc compound, cetylpyridinium chloride (CPC) and a pharmaceutically acceptable carrier.2. The oral composition of claim 1 , wherein the first and second components are stored separately.3. The oral composition of claim 1 , wherein the at least one E-raising compound is selected from the group consisting of hydrogen peroxide claim 1 , a fermentable sugar claim 1 , an oxyhalogen compound claim 1 , a biologically-compatible oxidation-reduction buffer claim 1 , and combinations thereof.4. The oral composition of claim 1 , wherein the at least one E-raising compound is selected from the group consisting of hydrogen peroxide and a fermentable sugar claim 1 , and wherein the first composition further comprises a chlorine-containing compound.5. The oral composition of claim 4 , wherein the chlorine-containing compound is selected from the group consisting of alkali metal chloride salts claim 4 , alkaline earth metal chloride salts claim 4 , and combinations thereof.6. The oral composition of claim 1 , wherein the at least one zinc compound is selected from the group consisting of zinc chloride claim 1 , zinc acetate claim 1 , zinc salicylate claim 1 , zinc sulfate claim 1 , zinc nitrate claim 1 , and combinations thereof.7. The oral composition of claim 1 , wherein the at least one E-raising compound is selected from the group consisting of hydrogen peroxide claim 1 , sodium chlorite and a fermentable sugar; and the zinc compound is selected from the ...

Подробнее
04-07-2013 дата публикации

CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR

Номер: US20130171105A1
Принадлежит: Synta Pharmaceuticals Corp.

A pharmaceutical combination comprising a topoisomerase II inhibitor, and an Hsp90 inhibitor according to the following formulae a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein. 23-. (canceled)4. The combination of claim 1 , wherein the Hsp90 inhibitor is 3-(2 claim 1 ,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1 claim 1 ,2 claim 1 ,4]triazole or a tautomer or a pharmaceutically acceptable salt thereof.5. The combination of claim 1 , wherein the Hsp90 inhibitor is 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1 claim 1 ,2 claim 1 ,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate claim 1 , or a tautomer claim 1 , or a pharmaceutically acceptable salt thereof.6. The combination according to claim 1 , wherein the topoisomerase II inhibitor is selected from the group consisting of etoposide claim 1 , amsacrine claim 1 , mitindomide claim 1 , teniposide claim 1 , doxorubicin claim 1 , daunorubicin claim 1 , idarubicin claim 1 , mitoxantrone claim 1 , anteniposide claim 1 , novobiocin claim 1 , dexrazoxane claim 1 , 3-hydroxy-2-[(1R)-6-isopropenyl-3-methyl-cyclohex-2-en-1-yl]-5-pentyl-1 claim 1 ,4-benzoquinone claim 1 , and 4-[2-(3 claim 1 ,5-dioxo-1-piperazinyl)-1-methylpropyl]piperazine-2 claim 1 ,6-dione.7. The combination according to claim 6 , wherein the topoisomerase II inhibitor is etoposide.8. The combination according to claim 1 , wherein the Hsp90 inhibitor is 3-(2 claim 1 ,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1 claim 1 ,2 claim 1 ,4]triazole claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof claim 1 , and the topoisomerase II inhibitor is etoposide.9. The combination according to claim 1 , wherein the Hsp90 inhibitor is 5-hydroxy-4-(5-hydroxy-4-(1- ...

Подробнее
04-07-2013 дата публикации

METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY

Номер: US20130171135A1
Принадлежит: F. Hoffmann-La Roche AG

The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. 1. A method of identifying a patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist , the method comprising:determining an expression level of unmodified VEGF in a sample obtained from the patient, wherein a level of unmodified VEGF in the sample obtained from the patient at or above a reference level indicates that the patient may benefit from treatment with the anti-cancer therapy.2. A method of predicting responsiveness of a patient suffering from cancer to treatment with an anti-cancer therapy comprising a VEGF-A antagonist , the method comprising:determining an expression level of unmodified VEGF in a sample obtained from the patient, wherein a level of unmodified VEGF in the sample obtained from the patient at or above a reference level indicates that the patient is more likely to be responsive to treatment with the anti-cancer therapy.3. A method for determining the likelihood that a patient with cancer will exhibit benefit from anti-cancer therapy comprising a VEGF-A antagonist , the method comprising:determining an expression level of unmodified VEGF in a sample obtained from the patient, wherein a level of unmodified VEGF in the sample obtained from the patient at or above a reference level indicates that the patient has increased likelihood of benefit from the anti-cancer therapy.4. A method for optimizing the therapeutic efficacy of an anti-cancer therapy comprising a VEGF-A antagonist , the method comprising:determining an expression level of unmodified VEGF in a sample obtained from the patient, wherein a level of unmodified VEGF in the sample obtained from the patient at or above a ...

Подробнее
04-07-2013 дата публикации

METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS

Номер: US20130171239A1
Автор: GILBARD Jeffrey
Принадлежит: Advanced Vision Research, Inc.

The instant invention provides preparations comprising an oxidizing antimicrobial agent such as chlorine dioxide and a heterocyclic compound that improves the antibacterial effect of the oxidizing antimicrobial agent preparation. The invention has particular use as an eye care preparation such as an eye drop. The invention further provides methods for reducing bacterial colonization and treating infection. 1. A preparation comprising an oxidizing antibacterial agent and a heterocyclic compound that improves the antibacterial effect of the oxidizing agent.2. The preparation of claim 1 , wherein the heterocyclic compound is a bicyclic compound.3. The preparation of claim 2 , wherein the heterocyclic compound is a xanthine.4. The preparation of claim 2 , wherein the bicyclic compound is selected from the group consisting of caffeine claim 2 , theophylline claim 2 , dyphylline claim 2 , theobromine claim 2 , xanthine claim 2 , xanthinol claim 2 , methylxanthine claim 2 , and aminophylline.5. The preparation of claim 4 , wherein the bicyclic compound is dyphylline.6. The preparation of wherein said oxidizing antibacterial agent is chlorine dioxide.7. The preparation of claim 6 , wherein the chlorine dioxide is present in a concentration of about 25-125 ppm.8. The preparation of claim 7 , wherein the chlorine dioxide is present in a concentration of about 50-75 ppm.9. The preparation of claim 8 , wherein the chlorine dioxide is present in a concentration of about 60 ppm.10. The preparation of claim 1 , wherein the preparation is in the form of a solution claim 1 , cream claim 1 , paste claim 1 , ointment claim 1 , or gel.11. The preparation of claim 1 , wherein the preparation is incorporated into a sustained-release carrier.12. The preparation of wherein said sustained-release carrier is selected from the group consisting of a sustained-release polymer claim 11 , a liposome and a microcapsule.13. The preparation of claim 1 , wherein the preparation is a solution.14. The ...

Подробнее
04-07-2013 дата публикации

Compositions and Methods for Enhancing the Effectiveness of Systemic, HIPEC, IP, and Related Cancer Treatments

Номер: US20130171271A1
Принадлежит: CHEMOTHERAPEUTICS, LLC

Methods for treating cancers, tumors, and neoplasms using a composition comprising one or more generally regarded as safe (GRAS) compounds selected from the group of components consisting of vitamins, selenium, fatty acids, fatty acid salts, and fatty acid esters, and mixtures of two or more said components, either as a stand-alone treatment or in combination with one or more anti-cancer drugs or devices or other anti-neoplastic agents, treatments, or devices are provided. In some instances, concomitant hyperthermia therapy is employed. Also provided are compositions and kits containing the compositions, for implement various aspects of the invention. 1. A method for killing cancer cells of a mammal comprising: contacting the cancer cells in vitro with one or more compounds selected from the group of Vitamin C , Selenium , or Quercetin; determining whether the cancer cells are affected in vitro by one or more compounds selected from the group of Vitamin C , Selenium , or Quercetin , and , if so; administering one or more compounds selected from the group of Vitamin C , Selenium , or Quercetin to the cancer cells of the mammal in vivo in an amount effective to kill cancer cells.2. A method for sensitizing cancer cells of a mammal to a therapeutic treatment comprising: contacting the cancer cells in vitro with one or more compounds selected from the group of Vitamin C , Selenium , or Quercetin; determining whether the cancer cells are sensitized in vitro to a therapeutic treatment by one or more compounds selected from the group of Vitamin C , Selenium , or Quercetin , and , if so; administering one or more compounds selected from the group of Vitamin C , Selenium , or Quercetin to the cancer cells of the mammal in vivo in an amount effective to sensitize the cancer cells to the therapeutic treatment.3. The method of claim 2 , wherein the therapeutic treatment is chemotherapy and comprises the administration of an effective amount of a chemotherapeutic agent to the ...

Подробнее
11-07-2013 дата публикации

Therapeutic Use of Tetrathiomolybdate

Номер: US20130177659A1
Принадлежит: Magnus TTM IC

Tetrathiomolybdate is for use in therapy of a condition requiring reduced metabolism of an organ or whole body, e.g. myocardial infection, stroke or ischaemia-reperfusion injury. 1. A method for providing therapy for a condition requiring reduced metabolism of an organ or whole body , wherein said method comprises administering , to a subject in need of such therapy , Tetrathiomolybdate (TTM).2. The method claim 1 , according to claim 1 , wherein the therapy is of ischemia-reperfusion injury.3. The method claim 2 , according to claim 2 , wherein the injury is of a head.4. The method claim 2 , according to claim 2 , wherein the injury is of a brain.5. The method claim 2 , according to claim 2 , wherein the therapy is for stroke.6. The method claim 2 , according to claim 2 , wherein the injury is of a heart.7. The method claim 6 , according to claim 6 , wherein the subject is undergoing a procedure selected from coronary artery bypass surgery claim 6 , open heart surgery and treatment for coronary artery thrombosis.8. The method claim 2 , according to claim 2 , wherein the injury is of a leg or kidney.9. The method claim 8 , according to claim 8 , wherein the subject is undergoing aortic cross-clamping for peripheral vascular surgery.10. The method claim 1 , according to claim 1 , wherein the therapy is for shock.11. The method claim 1 , according to claim 1 , wherein the therapy is for hypoxaemia.12. The method claim 1 , according to claim 1 , wherein the therapy is for haemorrhage.13. The method claim 1 , according to claim 1 , wherein the therapy is for cardiac arrest.14. A method for providing therapy to a subject that is undergoing a procedure that causes reperfusion or revascularisation claim 1 , wherein the method comprises administering to the subject Tetrathiomolybdate (TTM) and wherein the TTM mitigates the reperfusion or revascularisation.15. The method claim 14 , according to claim 14 , wherein the procedure is therapy for myocardial infarcton.16. The ...

Подробнее
11-07-2013 дата публикации

POTENTIATOR OF ACTIVITY OF ANTI-CANCER AGENT AND USE THEREOF, AND BIOMARKER FOR PREDICTION OF PROGNOSIS IN CANCER PATIENT AND USE THEREOF

Номер: US20130177660A1

Disclosed is a means for improving the clinical outcomes of cancer therapy. Specifically disclosed is an activity potentiator comprising a compound capable of inhibiting the expression of RFP (RET finger protein) gene or the activity of RFP as an active ingredient. The activity of an anti-cancer agent having an oxidative stress inducing ability can be potentiated by using the anti-cancer agent in combination with the activity potentiator. Further specifically disclosed are a biomarker useful for the recognition of prognosis in a cancer patient and use of the biomarker. 115-. (canceled)16. An action enhancing agent of an anticancer drug having an oxidative stress-inducing ability , comprising a compound , as an active ingredient , for suppressing expression of a RFP (RET finger protein) gene or action of RFP.17. The action enhancing agent according to claim 16 , wherein the compound is selected from the group consisting of the following (a) to (d):(a) siRNA targeting the RFP gene;(b) a nucleic acid construct for generating the siRNA targeting the RFP gene in a cell;(c) an antisense nucleic acid targeting a transcriptional product of the RFP gene; and(d) a ribozyme targeting a transcriptional product of the RFP gene.18. The action enhancing agent according to claim 16 , which is used in combination with an anticancer drug having an oxidative stress-inducing ability.19. A method for enhancing action of an anticancer drug having an oxidative stress-inducing ability claim 16 , the method comprising a step of suppressing expression of a RFP gene or action of RFP in a target cell.20. A method for treating a cancer claim 16 , the method comprising:{'claim-ref': {'@idref': 'CLM-00016', 'claim 16'}, 'a step of administering the action enhancing agent according to ; and'}a step of administering an anticancer drug having an oxidative stress-inducing ability.21. A method for testing resistance to an anticancer drug claim 16 , the method comprising:a step of examining an ...

Подробнее
18-07-2013 дата публикации

DRUG COMBINATIONS WITH FLUORO-SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS

Номер: US20130183268A1
Принадлежит: Bayer HealthCare LLC

The present invention relates to drug combinations and pharmaceutical compositions for treating hyperproliferative disorders such as cancer including non-small cell lung carcinoma, said drug combination comprising (1) a fluoro-substituted-diaryl urea of Formula (I), (2) at least one antifolate and optionally (3) at least one platinum complex antineoplastic nucleic acid binding agent, where any of these components can be present in the form of a pharmaceutically acceptable salt or other derivative thereof. 3. A combination of wherein the antifolate is Pemetrexed claim 1 , (S)-2-[4-[2-(4-amino-2-oxo-3 claim 1 ,5 claim 1 ,7-triazabicyclo[4.3.0]nona-3 claim 1 ,8 claim 1 ,10-trien-9-yl)ethyl]benzoyl]aminopentanedioic acid or a polymorph claim 1 , solvate claim 1 , hydrate claim 1 , metabolite claim 1 , prodrug claim 1 , pharmaceutically acceptable salt or an isolated diastereoisomer thereof.4. A combination of which additionally comprises (3) at least one platinum complex antineoplastic nucleic acid binding agent.5. A combination of wherein the platinum complex antineoplastic nucleic acid binding agent isCisplatin, (cis-diamminedichloroplatinum(II));Carboplatin, (cis-diammine(cyclobutane-1,1-dicarboxylate-O,O′)platinum(II);Oxaliplatin, ([(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O′)platinum(II));Tetraplatin or Ormaplatin ((1R,2R)-cyclohexane-1,2-diamine platinum(IV) tetrachloride)Satraplatin ((OC-6-43)bis(acetato)aminedichloro(cyclohexylamine)platinum), or a polymorph, solvate, hydrate, metabolite, prodrug, pharmaceutically acceptable salt or isolated diastereoisomer thereof.7. A combination of adapted for administration of components (1) and (2) to a patient in need thereof either(a) in the same formulation,(b) in separate formulations using the same administration route, or(c) in separate formulations using different administration routes.8. A combination of adapted for administration of components (1) claim 7 , (2) and (3) to a patient in need thereof either(a) ...

Подробнее
18-07-2013 дата публикации

NUTRIENT COMPOSITIONS AND METHODS FOR ENHANCED EFFECTIVENESS OF THE IMMUNE SYSTEM

Номер: US20130183277A1
Автор: Kaiser Jon D.
Принадлежит:

Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine. 127-. (canceled)28. A method of increasing a mammal's CD4+ cell count while undergoing therapy for treatment of a condition selected from the group consisting of immune-mediated diseases , cancer , heart disease , neurodegenerative disease , and infectious disease , comprising:administering to the mammal, during a treatment period, a nutrient composition and at least one drug effective for treatment of said condition; 1.43 mg to 11.42 mg alpha lipoic acid;', '3.57 mg to 28.58 mg acetyl L-carnitine; and', '4.28 mg to 34.28 mg N-acetyl-cysteine;, 'the nutrient composition comprising, in per kg body weight per daywhereby the mammal's CD4+ cell count is increased during the treatment period.29. The method of claim 28 , wherein the nutrient composition further comprises one or more vitamins or minerals selected from the group consisting of zinc claim 28 , selenium claim 28 , vitamin C claim 28 , bioflavinoid complex claim 28 , vitamin E claim 28 , beta-carotene claim 28 , vitamin A claim 28 , vitamin B1 claim 28 , vitamin B2 claim 28 , vitamin B6 claim 28 , niacinamide claim 28 , calcium panthothenate claim 28 , folic acid claim 28 , vitamin B12 claim 28 , copper claim 28 , manganese claim 28 , chromium claim 28 , and molybdenum;30. The method of claim 28 , wherein the alpha-lipoic acid claim 28 , acetyl L-carnitine claim 28 , and N-acetyl-cysteine are present in the nutrient composition in a ratio from 1:1:1 to 1:4:6.31. The method of claim 28 , wherein the treatment period is from about three to about twelve weeks.32. The method of claim 28 , wherein the treatment period is at least fifteen weeks.33. The method of claim 28 , ...

Подробнее
18-07-2013 дата публикации

Novel IDO Inhibitors and Methods of Use Thereof

Номер: US20130183388A1
Принадлежит: LANKENAU INSTITUTE FOR MEDICAL RESEARCH

Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed. 1. (canceled)3. (canceled)4. (canceled)5. A pharmaceutical composition for the treatment of cancer comprising a pharmaceutically acceptable carrier and an effective amount at least one indoleamine 2 claim 2 ,3-dioxygenase (IDO) inhibitor claim 2 , wherein at least one of said IDO inhibitors is the compound of .616-. (canceled)17. The pharmaceutical composition of claim 5 , further comprising at least one signal transduction inhibitor (STI).18. (canceled)19. (canceled)20. The pharmaceutical composition of claim 5 , further comprising at least one chemotherapeutic agent.21. (canceled)22. (canceled)23. The pharmaceutical composition of claim 20 , wherein said at least one chemotherapeutic agent is selected from the group consisting of paclitaxel (Taxol®) claim 20 , cisplatin claim 20 , docetaxol claim 20 , carboplatin claim 20 , vincristine claim 20 , vinblastine claim 20 , methotrexate claim 20 , cyclophosphamide claim 20 , CPT-11 claim 20 , 5-fluorouracil (5-FU) claim 20 , gemcitabine claim 20 , estramustine claim 20 , carmustine claim 20 , adriamycin (doxorubicin) claim 20 , etoposide claim 20 , arsenic trioxide claim 20 , irinotecan claim 20 , and epothilone derivatives.2434.-. (canceled)35. A compound which is the hydroquinone form of the compound of .36. (canceled)37. The compound of claim 2 , wherein X claim 2 , X claim 2 , X claim 2 , X claim 2 , X claim 2 , X claim 2 , and Xare H.38. The compound of claim 2 , wherein Xis R.39. The compound of claim 38 , wherein R is aryl.40. The compound of claim 37 , wherein Xis R.41. The compound of claim 39 , wherein R is aryl. This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 60/918,516, filed on Mar. 16, 2007. The foregoing application is incorporated by reference herein.Pursuant to 35 U.S.C. Section 202(c), it is acknowledged that the United ...

Подробнее
18-07-2013 дата публикации

Synthesis of fluorescent noble metal nanoparticles

Номер: US20130183665A1
Принадлежит: University of Toronto

A process for the production of fluorescent nanoparticles selected from noble metal, silica or polymer nanoparticles which comprises: 1. A process for the production of fluorescent nanoparticles selected from noble metal or silica nanoparticles which comprises: (1) providing a platform of nanoparticles; (2) covering the surfaces of the nanoparticles to saturation with thiol-terminated polymers by one of the following methods: 1. mixing the nanoparticles with methoxy-(polyethylene glycol)-thiol and biotin-(polyethylene glycol)-thiol; 2. mixing the nanoparticles with fluorescently-labeled methoxy-(polyethylene glycol)-thiol and/or biotin-(polyethylene glycol)-thiol 3. coordinating thiol and biotin thiol to the surfaces of the nanoparticles by a non-covalent bond; and 4. directly conjugating methoxy-thiol and biotin-thiol to the surfaces of the nanoparticles, so that the polymers bind to the surfaces of the nanoparticles as a brush layer via thiol particle coordination of the thiol ends so that the biotin or methoxy ends are free; and (3) homogeneously mixing the resulting biotin nanoparticles with fluorescent avidin or a derivative thereof in proportions such that the final concentration is 1 biotin molecule for every 10 to 1000 avidin molecules in the fluorescent multi-coloured nanoparticle-avidin complexes, each being capable of having a different targeting molecule, and which may be mixed with biotin related targets, and the fluorescent labeled avidin or a derivative thereof being spaced away from the particle surface, thus reducing or removing the potential quenching of the dye.

Подробнее
25-07-2013 дата публикации

Wound care system and bacteridical methods and devices

Номер: US20130189345A1

A variety of article and systems including wound care systems, methods for making the wound care systems, bactericidal, and methods for treating wounds using these systems are disclosed. The wound care systems may include a first material comprising one or more fibers or porous media. The one or more fibers or porous media may be coated with a second material that is capable of inhibiting the growth of bacteria and killing the bacteria to render the wound care system sterile, increasing the absorbency of the first material, or both upon exposure to light. The first material may be cotton, or any suitable fibrous material, the second material may be TiO 2 , and the light may be UV or visible light. A variety of methods including ALD may be used to coat the first material.

Подробнее
25-07-2013 дата публикации

Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections

Номер: US20130189364A1
Автор: Robert Sabin
Принадлежит: Individual

A composition and method for potentiating, sensitizing, and/or amplifying at least one adjuvant pharmaceutical targeting at least one latent viral infection in a patient is provided. In one embodiment, the composition is administered to potentiate, sensitize and/or amplify an adjuvant pharmaceutical targeting at least one latent viral infection such as those which are currently being investigated for use with anti-HIV drugs/antiretrovirals HAART.

Подробнее
25-07-2013 дата публикации

METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION

Номер: US20130189374A1
Принадлежит: DRUGTECH CORPORATION

The present invention generally relates to methods and compositions useful in enhancing iron absorption in a patient. The methods and compositions of the present invention may be used independently to promote and/or maintain iron absorption in a patient or may be used in combination with one or more other compositions used in the treatment of one or more diseases having iron deficiency associated therewith. 1. A composition for increasing iron absorption in a patient , the composition comprising:(a) a first iron promoter comprising a compound having Vitamin C activity; and(b) a second iron promoter comprising an organic acid selected from the group consisting of succinic acid, acetic acid, citric acid, lactic acid, malic acid, glutamic acid, salts of succinic acid, salts of acetic acid, salts of citric acid, salts of lactic acid, salts of malic acid, salts of glutamic acid, derivatives of succinic acid, derivatives of acetic acid, derivatives of citric acid, derivatives of lactic acid, derivatives of malic acid, derivatives of glutamic acid, and combinations thereof;wherein the first iron absorption promoter is formulated to dissolve in less than about 180 minutes following oral administration to the patient; andwherein the second iron promoter is formulated for extended release such that less than substantially all of the second iron promoter dissolves within about 180 minutes following oral administration of the composition to a patient and substantially all of the second iron promoter dissolves in less than about 48 hours following oral administration of the composition to a patient.2. The composition of claim 1 , wherein the compound having Vitamin C activity is selected from the group consisting of L-ascorbic acid claim 1 , calcium ascorbate claim 1 , sodium ascorbate claim 1 , magnesium ascorbate claim 1 , potassium ascorbate claim 1 , zinc ascorbate claim 1 , L-threonic acid claim 1 , L-xylonic acid and L-lyxonic acid.3. The composition of claim 1 , wherein ...

Подробнее
01-08-2013 дата публикации

Methods for Reducing Cholesteron Using Bacillus Coagulans Spores, Systems and Compositions

Номер: US20130195824A1
Принадлежит: Ganeden Biotech Inc

The invention describes therapeutic compositions including a lactic acid-producing bacteria, such as isolated Bacillus coagulans, in combination with a cholesterol-reducing agent for use in reducing LDL cholesterol and serum triglycerides. Also described are therapeutic methods using the compositions and systems containing the therapeutic compositions.

Подробнее
01-08-2013 дата публикации

CERIUM OXIDE NANOPARTICLES AND ASSOCIATED METHODS FOR PROMOTING WOUND HEALING

Номер: US20130195927A1
Автор: DAS Soumen, Sudipta Seal

Novel compositions and methods for the treatment and promotion of wound healing are disclosed herein. There is included a method for treating a wound including administering to a subject in need thereof a wound composition comprising an effective amount of ceria nanoparticles. 1. A method for treating a wound comprising administering to a subject in need thereof a wound composition comprising an effective amount of ceria nanoparticles.2. The method of claim 1 , wherein the wound composition is administered via topical administration.3. The method of claim 2 , wherein the wound composition is in a form from the group consisting of a solution claim 2 , a suspension claim 2 , a spray claim 2 , a cream claim 2 , a gel claim 2 , a foam claim 2 , an ointment claim 2 , a lotion claim 2 , or a powder.3. The method of claim 1 , wherein the wound composition is administered via parenteral administration.4. The method of claim 1 , wherein the effective amount of ceria nanoparticles is at least 1 μM.5. The method of claim 1 , wherein the effective amount of ceria nanoparticles is least 10 μM.6. The method of claim 1 , wherein the ceria nanoparticles comprise nanoparticles having a diameter of from about 3 nm to about 5 nm.7. The method of claim 1 , wherein the ceria nanoparticles are in form of agglomerates having an diameter of 50 nm or less.8. The method of claim 1 , wherein the wound is at least one of a wound selected from the group consisting of an incomplete healing wound claim 1 , a chronic wound claim 1 , a burn claim 1 , and a wound caused by trauma.9. The method of claim 8 , wherein the wound is a diabetic ulcer.10. The method of claim 1 , wherein the administration is done by applying a dressing comprising an effective amount of ceria nanoparticles at claim 1 , over claim 1 , or adjacent the wound of the subject claim 1 , the dressing selected from the group consisting of a transdermal patch claim 1 , a pad claim 1 , a powder claim 1 , a matrix claim 1 , and a ...

Подробнее